<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults - Hnin, K - 2015 | Cochrane Library</title> <meta content="Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults - Hnin, K - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001392.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults - Hnin, K - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001392.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001392.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults" name="citation_title"/> <meta content="Khin Hnin" name="citation_author"/> <meta content="Flinders University" name="citation_author_institution"/> <meta content="Chau Nguyen" name="citation_author"/> <meta content="Queen Elizabeth Hospital" name="citation_author_institution"/> <meta content="Kristin V Carson‐Chahhoud" name="citation_author"/> <meta content="The University of Adelaide" name="citation_author_institution"/> <meta content="kristin.carson@adelaide.edu.au" name="citation_author_email"/> <meta content="David J Evans" name="citation_author"/> <meta content="Hemel Hempstead Hospital" name="citation_author_institution"/> <meta content="Michael Greenstone" name="citation_author"/> <meta content="Castle Hill Hospital" name="citation_author_institution"/> <meta content="Brian J Smith" name="citation_author"/> <meta content="The Queen Elizabeth Hospital, Central Adelaide Local Health Network" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD001392.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/08/13" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001392.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001392.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001392.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Bacterial Agents [*administration &amp; dosage, adverse effects]; Bronchiectasis [*drug therapy, microbiology]; Diarrhea [chemically induced]; Disease Progression; Drug Resistance, Bacterial; Hospitalization [statistics &amp; numerical data]; Odds Ratio; Randomized Controlled Trials as Topic; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001392.pub3&amp;doi=10.1002/14651858.CD001392.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001392\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001392\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001392.pub3",title:"Prolonged antibiotics for non\\u2010cystic fibrosis bronchiectasis in children and adults",firstPublishedDate:"Aug 13, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001392.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001392.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001392.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001392.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001392.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001392.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001392.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001392.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001392.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001392.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2286 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001392.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-sec-0089"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/appendices#CD001392-sec-0094"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/table_n/CD001392StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/table_n/CD001392StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prolonged antibiotics for non‐cystic fibrosis bronchiectasis in children and adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#CD001392-cr-0002">Khin Hnin</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#CD001392-cr-0003">Chau Nguyen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#CD001392-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Kristin V Carson‐Chahhoud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#CD001392-cr-0005">David J Evans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#CD001392-cr-0006">Michael Greenstone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information#CD001392-cr-0007">Brian J Smith</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information/en#CD001392-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 13 August 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001392.pub3">https://doi.org/10.1002/14651858.CD001392.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001392-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001392-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001392-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001392-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001392-abs-0001" lang="en"> <section id="CD001392-sec-0001"> <h3 class="title" id="CD001392-sec-0001">Background</h3> <p>The vicious cycle hypothesis for bronchiectasis predicts that bacterial colonisation of the respiratory tract perpetuates inflammatory change. This damages the mucociliary escalator, preventing bacterial clearance and allowing persistence of pro‐inflammatory mediators. Conventional treatment with physiotherapy and intermittent antibiotics is believed to improve the condition of people with bronchiectasis, although no conclusive data show that these interventions influence the natural history of the condition. Various strategies have been tried to interrupt this cycle of infection and inflammation, including prolonging antibiotic treatment with the goal of allowing the airway mucosa to heal. </p> </section> <section id="CD001392-sec-0002"> <h3 class="title" id="CD001392-sec-0002">Objectives</h3> <p>To determine the benefits of prolonged antibiotic therapy in the treatment of patients with bronchiectasis. </p> </section> <section id="CD001392-sec-0003"> <h3 class="title" id="CD001392-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Trials Register and reference lists of identified articles. Searches were current as of February 2014. </p> </section> <section id="CD001392-sec-0004"> <h3 class="title" id="CD001392-sec-0004">Selection criteria</h3> <p>Randomised trials examining the use of prolonged antibiotic therapy (for four or more weeks) in the treatment of bronchiectasis compared with placebo or usual care. </p> </section> <section id="CD001392-sec-0005"> <h3 class="title" id="CD001392-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. We contacted study authors to ask for missing information. </p> </section> <section id="CD001392-sec-0006"> <h3 class="title" id="CD001392-sec-0006">Main results</h3> <p>Eighteen trials met the inclusion criteria, randomly assigning a total of 1157 participants. Antibiotics were given for between four weeks and 83 weeks. Limited meta‐analysis was possible because of the diversity of outcomes reported in these trials. Based on the number of participants with at least one exacerbation, the meta‐analysis showed significant effects in favour of the intervention (odds ratio (OR) 0.31, 95% confidence interval (CI) 0.19 to 0.52; P value &lt; 0.00001), with events occurring in 271 per 1000 people in the intervention arm (95% CI 126 to 385) and in 546 per 1000 in the control population, based on evidence of moderate quality. A non‐statistically significant reduction in hospitalisation favoured the use of prolonged antibiotics with a moderate quality grade of supporting evidence (37 per 1000 in the intervention arm (95% CI 13 to 96) and 87 per 1000 in control (OR 0.40, 95% CI 0.14 to 1.11; P value = 0.08). Drug resistance developed in 36 of 220 participants taking antibiotics compared with 10 of 211 participants given placebo or standard therapy (OR 3.48, 95% CI 1.20 to 10.07; P value = 0.02), translating to natural frequencies of 155 per 1000 in the intervention arm (95% CI 59 to 346) and 50 per 1000 in the control arm. The intervention was well tolerated with no overall significant difference in withdrawal between treatment and placebo groups (OR 0.91, 95% CI 0.56 to 1.49). Diarrhoea was commonly reported as an adverse event, particularly with an oral intervention. </p> </section> <section id="CD001392-sec-0007"> <h3 class="title" id="CD001392-sec-0007">Authors' conclusions</h3> <p>Available evidence shows benefit associated with use of prolonged antibiotics in the treatment of patients with bronchiectasis, at least halving the odds of exacerbation (with 275 fewer exacerbations per every 1000 people treated in the antibiotic arm compared with the control arm) and hospitalisation (50 fewer hospitalisations per 1000 people in the antibiotic arm compared with the control arm). However, the risk of emerging drug resistance is increased more than threefold. This review is limited by diversity of trials and by evidence of moderate to low quality. Further randomised controlled trials with adequate power and standardised end points are required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001392-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001392-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001392-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001392-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001392-abs-0004">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001392-abs-0003" lang="en"> <h3>Prolonged antibiotics for purulent bronchiectasis in children and adults</h3> <p><b>Does prolonged antibiotic therapy provide benefit in treatment of patients with purulent bronchiectasis?</b> </p> <p><b>Why is this question important?</b> </p> <p>Non‐cystic fibrosis (CF) bronchiectasis is a chronic respiratory condition characterised by abnormal dilatation of the airways. Although its global prevalence is largely unknown, available data from Australia, New Zealand, the United States and England show that bronchiectasis is now diagnosed with increasing frequency. The lungs of patients with bronchiectasis have excessive secretions, which tend to consist of different types of micro‐organisms. Long‐term antibiotic therapy was proposed to halt persistent and ongoing damage to the lung due to insult from micro‐organisms. Therefore, we seek to assess the effects of prolonged antibiotic therapy on patients with bronchiectasis. </p> <p><b>How did we answer the question?</b> </p> <p>We looked for all studies comparing prolonged antibiotic therapy versus usual care and/or a dummy medication (placebo). </p> <p><b>What did we find?</b> </p> <p>We found 18 studies including 1157 people with non‐cystic fibrosis bronchiectasis; most were adults. Twelve studies used a tablet form of antibiotics (e.g. azithromycin, erythromycin, roxithromycin, amoxycillin, clarithromycin, penicillin, oxytetracycline, ciprofloxacin). The remaining six studies reported use of inhaled medications. Antibiotics were given for between four weeks and 83 weeks. In seven studies, similar disease severity at baseline was supported by the similar history of previous hospitalisation and severe attacks. </p> <p>Overall quality of evidence was rated as moderate. When an outcome is rated as high quality, further research is very unlikely to change our confidence in the estimate of effect, but moderate ratings reflect some uncertainty in the findings. </p> <p><b>Conclusion</b> </p> <p>Prolonged antibiotic therapy in bronchiectasis provides benefit, especially in reducing the risk of future exacerbations and hospitalisations. Antibiotics are well tolerated by participants without significant differences in overall adverse effects (e.g. intolerance, chest symptoms, fatigue, fever, palpitations). </p> <p>However, antibiotic resistance is a matter of concern, particularly for patients with drug allergies, which further limit their future treatment. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001392-sec-0089" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001392-sec-0089"></div> <h3 class="title" id="CD001392-sec-0090">Implications for practice</h3> <section id="CD001392-sec-0090"> <p>This review has demonstrated a positive effect for prolonged antibiotics in bronchiectasis at the cost of emergence of resistance. Available data support the use of prolonged courses of antibiotics in selected patients. </p> </section> <h3 class="title" id="CD001392-sec-0091">Implications for research</h3> <section id="CD001392-sec-0091"> <p>Further trials are required to examine this question in relation to issues surrounding the management of <i>Pseudomonas aeruginosa</i> colonisation, which should be addressed separately, as should the question of route of administration. A non‐antibacterial effect of macrolide antibiotics should also be sought. Possible adverse effects intervention based on route of administration of the intervention, particularly patient tolerance, should be monitored in future studies. These new trials should be appropriately powered and of adequate duration. They should have standardised endpoints and should report baseline characteristics of participants, particularly extent of disease (lung function, radiological extent/lobes involved), disease burden (baseline exacerbation, hospitalisation, sputum volume and purulence), smoking status and co‐morbidities. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001392-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001392-sec-0015"></div> <div class="table" id="CD001392-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prolonged antibiotics for purulent bronchiectasis in children and adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prolonged antibiotics for purulent bronchiectasis in children and adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with purulent bronchiectasis<br/> <b>Settings:</b> <br/> <b>Intervention:</b> prolonged antibiotics </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Prolonged antibiotics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations</b> <br/> Number of events<br/> Follow‐up: 1.5 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>546 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>271 per 1000</b> <br/> (126 to 385) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.31</b> <br/> (0.12 to 0.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>654<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 studies reported data on hospitalisations; 10 dichotomous studies are reported here. Generic inverse variance combining dichotomous and continuous data produced statistical significance in favour of antibiotic arm (OR 0.31, 95% CI 0.19 to 0.52; I² = 51%; P value &lt; 0.00001) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisations</b> <br/> Number of events<br/> Follow‐up: 1.5 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> <br/> (13 to 96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> <br/> (0.14 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>643<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over study <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> (n = 30 participants) also reported on hospitalisations with mean (± SD) improvement of 0.15 ± 0.37 observed in antibiotic arm compared with 0.75 ± 1.16 in placebo arm at 13 month follow‐up </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergence of resistance</b> <br/> Number of events<br/> Follow‐up: 1.5 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> <br/> (56 to 334) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.48</b> <br/> (1.20 to 10.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>431<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nine studies reported on emergence of resistance; however, because of variability in reporting of outcome data, only 6 could be meta‐analysed. No difference was observed between groups for the remaining 3 studies </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>St George Respiratory Questionnaire (SGRQ) total</b> <br/> Mean and standard deviation. Scale from 0 to 100<br/> Follow‐up: 6 to 16 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ (total) score ranged across control groups from<br/> <b>‐6.4 to 4.1 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ (total) score in intervention groups was<br/> <b>2.75 lower</b> <br/> (7.08 lower to 1.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life was reported in 10 studies, with meta‐analysis possible in 5. Substantial heterogeneity was observed between studies. Although sensitivity analysis using a fixed‐effect model produced statistically significant results, primary analysis using a random‐effects model was not statistically significant </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Presence of heterogeneity in 30% to 60% range, representing possibility of moderate heterogeneity.<br/> <sup>b</sup>Small number of events producing wide confidence intervals around estimate of effect.<br/> <sup>c</sup>Presence of heterogeneity in 75% to 100% range, representing possibility of considerable heterogeneity. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001392-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001392-sec-0016"></div> <section id="CD001392-sec-0017"> <h3 class="title" id="CD001392-sec-0017">Description of the condition</h3> <p>Non‐cystic fibrosis (CF) bronchiectasis is a chronic respiratory condition characterised by abnormal dilatation of the bronchial lumen (<a href="./references#CD001392-bbs2-0267" title="LoebingerM . Mortality in bronchiectasis: a long‐term study assessing the factors influencing survival. European Respiratory Journal2009;34(4):843‐9. ">Loebinger 2009</a>; <a href="./references#CD001392-bbs2-0272" title="O'DonnellAE . Bronchiectasis. Chest2008;134(4):815‐23. ">O'Donnell 2008</a>). Global prevalence of this disorder is largely unknown (<a href="./references#CD001392-bbs2-0265" title="KwakHJ . High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. The Tohoku Journal of Experimental Medicine2010;222:237‐42. ">Kwak 2010</a>; <a href="./references#CD001392-bbs2-0268" title="MaguireG . Bronchiectasis: a guide for primary care. Australian Family Physician2012;41:842‐50. ">Maguire 2012</a>), primarily because bronchiectasis may be noted as a secondary diagnosis for other conditions (<a href="./references#CD001392-bbs2-0253" title="Australian Institute of Health and Welfare. Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia. http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 (accessed 13 November 2014). [URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 [date accessed 18/07/2014]] ">AIHW 2010</a>). Formal diagnosis requires special investigation and therefore usually occurs only among patients referred to a respiratory specialist (<a href="./references#CD001392-bbs2-0253" title="Australian Institute of Health and Welfare. Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia. http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 (accessed 13 November 2014). [URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 [date accessed 18/07/2014]] ">AIHW 2010</a>). However, available data on prevalence show that bronchiectasis is now being diagnosed with increasing frequency (<a href="./references#CD001392-bbs2-0270" title="Martínez GarcíaM , Máiz CarroL , Catalán SerraP . Treatment of non‐cystic fibrosis bronchiectasis. Archivos de Bronconeumologia2011;47:599‐609. ">Martínez‐García 2011</a>; <a href="./references#CD001392-bbs2-0271" title="McShanePJ , NaureckasET , TinoG , StrekME . Non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2013;188:647‐56. ">McShane 2013</a>; <a href="./references#CD001392-bbs2-0272" title="O'DonnellAE . Bronchiectasis. Chest2008;134(4):815‐23. ">O'Donnell 2008</a>). In the United States of America (USA), <a href="./references#CD001392-bbs2-0279" title="SeitzAE , OlivierKN , AdjemianJ , HollandSM , PrevotsR . Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest2012;142:432‐9. ">Seitz 2012</a> found an increasing yearly prevalence from 2000 to 2007, with an annual percentage change of 8.74%. Prevalence estimates in the USA range from 4.2 per 100,000 persons 18 to 34 years of age to 271.8 per 100,000 among those 75 years of age and older (<a href="./references#CD001392-bbs2-0285" title="WeyckerD , EdelsbergJ , OsterG , TinoG . Prevalence and economic burden of bronchiectasis. Clinical Pulmonary Medicine2005;12:205‐9. ">Weycker 2005</a>). In Finland, the incidence of non‐CF bronchiectasis among children younger than 15 years has been estimated at 0.5 per 100,000 per year and at 3.9 per 100,000 for the overall population (<a href="./references#CD001392-bbs2-0278" title="SaynajakangasO , KeistinenT , TuuponenT , KivelaSL . Evaluation of the incidence and age distribution of bronchiectasis from the Finnish hospital discharge register. Central European Journal of Public Health1998;6:235‐7. ">Saynajakangas 1998</a>). Higher prevalence estimates have been reported in children living in Northern England with 17.2 per 100,000 per year diagnosed, and in New Zealand with estimates of 3.7 per 100,000 (<a href="./references#CD001392-bbs2-0283" title='TwissJ , MetcalfeR , EdwardsE , ByrnesC . New Zealand national incidence of bronchiectasis "too high" for a developed country. Archives of Disease in Childhood2005;90:737‐40. '>Twiss 2005</a>). In Australia, however, bronchiectasis among Aboriginal and Torres Strait Islander children is estimated to occur in as many as 14 per 1000 Indigenous youth (<a href="./references#CD001392-bbs2-0257" title="ChangA , GrimwoodK , MulhollandE , TorzilloP . Bronchiectasis in indigenous children in remote Australian communities. Medical Journal of Australia2002;177:200‐4. ">Chang 2002</a>), with similar statistics reported when New Zealand children of Pacific and Maōri origin were compared with children of European ancestry (<a href="./references#CD001392-bbs2-0283" title='TwissJ , MetcalfeR , EdwardsE , ByrnesC . New Zealand national incidence of bronchiectasis "too high" for a developed country. Archives of Disease in Childhood2005;90:737‐40. '>Twiss 2005</a>). Statistics indicate that prevalence increases with age and peaks at around 80 years, and that higher rates have been observed among women (<a href="./references#CD001392-bbs2-0253" title="Australian Institute of Health and Welfare. Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia. http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 (accessed 13 November 2014). [URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 [date accessed 18/07/2014]] ">AIHW 2010</a>; <a href="./references#CD001392-bbs2-0266" title="LeeYM . The clinical characteristics of patients with non‐CF bronchiectasis. Chest2011;140:459A. ">Lee 2011</a>; <a href="./references#CD001392-bbs2-0279" title="SeitzAE , OlivierKN , AdjemianJ , HollandSM , PrevotsR . Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000 to 2007. Chest2012;142:432‐9. ">Seitz 2012</a>). </p> <p>The underlying pathogenesis of non‐CF bronchiectasis is not entirely understood (<a href="./references#CD001392-bbs2-0286" title="WilsonR , HansellDM , LoebingerMR . Definition and aetiology of non‐CF bronchiectasis. In: BlasiF , MiravitllesM editor(s). The Spectrum of Bronchial Infection. Sheffield: European Respiratory Society, 2013:107‐19. [ISBN: 978‐1‐84984‐034‐7 ] ">Wilson 2013b</a>). In most patients, the airways become chronically infected with a variety of pathogens involved in the aetiology of this condition (<a href="./references#CD001392-bbs2-0255" title="ChalmersJD , SmithMP , McHughBJ , DohertyC , GovanJR , HillAT . Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;186(7):657‐65. ">Chalmers 2012</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0282" title="TunneyM . Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. American Journal of Respiratory and Critical Care Medicine2013;187(10):1118‐26. ">Tunney 2013</a>), including <i>Haemophilus influenzae</i> (which dominates across all ages),<i>Streptococcus pneumoniae, Moraxella catarrhalis</i> and <i>Pseudomonas aeruginosa</i> (<a href="./references#CD001392-bbs2-0261" title="GrimwoodK . Airway microbiology and host defences in paediatric non‐CF bronchiectasis. Paediatric Respiratory Reviews2011;12:111‐8. ">Grimwood 2011</a>)<i>.</i> The landmark study by <a href="./references#CD001392-bbs2-0275" title="ReidLM . Reduction in bronchial subdivision in bronchiectasis. Thorax1950;5:233‐47. ">Reid 1950</a> first refined pathological phenotypes as cylindrical, varicose and saccular, and <a href="./references#CD001392-bbs2-0258" title="ColePJ . Inflammation: a two‐edged sword—the model of bronchiectasis. European Journal of Respiratory Diseases Supplement1986;147:6‐15. ">Cole 1986</a> further explained the evolution of bronchiectasis through the vicious cycle model. This model continues to be adapted but generally describes development of a vicious cycle of infection and inflammation whereby symptoms persist, with frequent exacerbations causing further airway damage (<a href="./references#CD001392-bbs2-0258" title="ColePJ . Inflammation: a two‐edged sword—the model of bronchiectasis. European Journal of Respiratory Diseases Supplement1986;147:6‐15. ">Cole 1986</a>; <a href="./references#CD001392-bbs2-0264" title="KingPT . The pathophysiology of bronchiectasis. International Journal of Chronic Obstructive Pulmonary Disease2009;4:411‐9. ">King 2009</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0272" title="O'DonnellAE . Bronchiectasis. Chest2008;134(4):815‐23. ">O'Donnell 2008</a>). Idiopathic bronchiectasis is the most common diagnosis and tends to be bilateral, cylindrical and lower lobe predominant (<a href="./references#CD001392-bbs2-0286" title="WilsonR , HansellDM , LoebingerMR . Definition and aetiology of non‐CF bronchiectasis. In: BlasiF , MiravitllesM editor(s). The Spectrum of Bronchial Infection. Sheffield: European Respiratory Society, 2013:107‐19. [ISBN: 978‐1‐84984‐034‐7 ] ">Wilson 2013b</a>). Severe infections of any type can damage the bronchial wall sufficiently to induce bronchiectasis localised to the site of infection (<a href="./references#CD001392-bbs2-0286" title="WilsonR , HansellDM , LoebingerMR . Definition and aetiology of non‐CF bronchiectasis. In: BlasiF , MiravitllesM editor(s). The Spectrum of Bronchial Infection. Sheffield: European Respiratory Society, 2013:107‐19. [ISBN: 978‐1‐84984‐034‐7 ] ">Wilson 2013b</a>). The next most common aetiologies are allergic bronchopulmonary aspergillosis, common variable immunodeficiency and primary ciliary dyskinesia (<a href="./references#CD001392-bbs2-0286" title="WilsonR , HansellDM , LoebingerMR . Definition and aetiology of non‐CF bronchiectasis. In: BlasiF , MiravitllesM editor(s). The Spectrum of Bronchial Infection. Sheffield: European Respiratory Society, 2013:107‐19. [ISBN: 978‐1‐84984‐034‐7 ] ">Wilson 2013b</a>). </p> <p>Bronchiectasis causes significant morbidity and increased risks for mortality. Typically patients will suffer with persistent cough, chronic daily sputum expectoration, recurrent chest infection and poor health‐related quality of life (<a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>). Mortality was examined in one recent Belgium cohort analysis of 245 participants newly diagnosed between 2006 and 2012; analysis revealed increased risk of death among participants with co‐morbid chronic obstructive pulmonary disease (COPD) compared with participants with other bronchiectasis (<a href="./references#CD001392-bbs2-0260" title="GoeminnePC , NawrotTS , RuttensD , SeysS , DupontLJ . Mortality in non‐cystic fibrosis bronchiectasis: a prospective cohort analysis. Respiratory Medicine2014;108(2):287‐96. ">Goeminne 2014</a>). However, national statistics in Australia show that only a small number of reported deaths are directly attributable to bronchiectasis (<a href="./references#CD001392-bbs2-0253" title="Australian Institute of Health and Welfare. Asthma, chronic obstructive pulmonary disease and other respiratory diseases in Australia. http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 (accessed 13 November 2014). [URL: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442453795 [date accessed 18/07/2014]] ">AIHW 2010</a>). A long‐term survival study that provided 13 years of follow‐up among 91 individuals with non‐CF bronchiectasis in the United Kingdom found that mortality, as was reported in 29.7% of participants, was associated with a degree of restrictive and obstructive disease, poor gas transfer and chronic <i>Pseudomonas</i> infection (<a href="./references#CD001392-bbs2-0267" title="LoebingerM . Mortality in bronchiectasis: a long‐term study assessing the factors influencing survival. European Respiratory Journal2009;34(4):843‐9. ">Loebinger 2009</a>). Additional risk factors observed to lower the likelihood of survival included increasing age and greater numbers of lobes affected (<a href="./references#CD001392-bbs2-0260" title="GoeminnePC , NawrotTS , RuttensD , SeysS , DupontLJ . Mortality in non‐cystic fibrosis bronchiectasis: a prospective cohort analysis. Respiratory Medicine2014;108(2):287‐96. ">Goeminne 2014</a>). </p> </section> <section id="CD001392-sec-0018"> <h3 class="title" id="CD001392-sec-0018">Description of the intervention</h3> <p>Recent evidence has helped improve our understanding of the role of mucus stasis in bacterial colonisation and has led to emphasis on therapies that enhance airway clearance (<a href="./references#CD001392-bbs2-0271" title="McShanePJ , NaureckasET , TinoG , StrekME . Non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2013;188:647‐56. ">McShane 2013</a>). Low‐dose, long‐term macrolide therapy has been shown to decrease exacerbation frequency and airway inflammation (<a href="./references#CD001392-bbs2-0271" title="McShanePJ , NaureckasET , TinoG , StrekME . Non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2013;188:647‐56. ">McShane 2013</a>). Long‐term use of antibiotics may provide benefit by reducing exacerbations but currently is not recommended as part of routine treatment (<a href="./references#CD001392-bbs2-0284" title="ValeryP , MorrisP , GrimwoodK , TorzilloP , ByrnesC , MastersIB , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomized controlled trial. BMC Paediatrics2012;12:122. ">Valery 2012</a>; <a href="./references#CD001392-bbs2-0287" title="WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Wu 2014</a>). However, for patients with three or more exacerbations per year requiring antibiotic therapy, or for those with fewer exacerbations causing significant morbidity, prolonged antibiotic therapy should be considered (<a href="./references#CD001392-bbs2-0274" title="PasteurMC , BiltonD , HillAT , British Thoracic Society Bronchiectasis non‐CF Guideline Group. British Thoracic Society guideline for non‐CF bronchiectasis. Thorax2010;65:i1‐i58. ">Pasteur 2010</a>). Long‐term use of inhaled antibiotics is believed to be safe and effective in reducing the sputum bacterial load, as these agents deliver a high concentration of drug to the airway along with reduced systemic absorption, thereby reducing the risk of systemic adverse effects (<a href="./references#CD001392-bbs2-0271" title="McShanePJ , NaureckasET , TinoG , StrekME . Non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2013;188:647‐56. ">McShane 2013</a>). However, most data supporting the use of tobramycin, gentamycin and colistin compounded or re‐constituted into a nebulised form for the management of bronchiectasis have come from studies on the CF population (<a href="./references#CD001392-bbs2-0271" title="McShanePJ , NaureckasET , TinoG , StrekME . Non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2013;188:647‐56. ">McShane 2013</a>), thus limiting the generalisability of findings to the non‐CF bronchiectasis population. </p> </section> <section id="CD001392-sec-0019"> <h3 class="title" id="CD001392-sec-0019">How the intervention might work</h3> <p>Various strategies have been developed to interrupt the vicious cycle model of <a href="./references#CD001392-bbs2-0258" title="ColePJ . Inflammation: a two‐edged sword—the model of bronchiectasis. European Journal of Respiratory Diseases Supplement1986;147:6‐15. ">Cole 1986</a>, whereby a repetitious syndrome of cough, sputum production and recurrent exacerbations is said to be the primary cause of bronchiectasis. If bacteria are the primary cause of airway inflammation, then according to this hypothesis, bacterial clearance through the use of short‐ or long‐term antibiotics should reduce airway inflammation (<a href="./references#CD001392-bbs2-0255" title="ChalmersJD , SmithMP , McHughBJ , DohertyC , GovanJR , HillAT . Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;186(7):657‐65. ">Chalmers 2012</a>; <a href="./references#CD001392-bbs2-0259" title="DowneyDG , BrockbankS , MartinSL , EnnisM , ElbornJS . The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatric Pulmonology2007;42(8):729‐35. ">Downey 2007</a>; <a href="./references#CD001392-bbs2-0273" title="OrdonezCL , HenigNR , Mayer‐HamblettN , AccursoFJ , BurnsJL , ChmielJF , et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine2003;168(12):1471‐5. ">Ordonez 2003</a>; <a href="./references#CD001392-bbs2-0276" title="SagelSD , KapsnerR , OsbergI , SontagMK , AccursoFJ . Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. American Journal of Respiratory and Critical Care Medicine2011;164:1425‐31. ">Sagel 2011</a>). Reducing inflammation would effectively allow time for airway healing and ultimately would modify the long‐term course of the disease (<a href="./references#CD001392-bbs2-0289" title="EvansDJ , BaraAI , GreenstoneM . Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD001392.pub2] ">Evans 2007</a>; <a href="./references#CD001392-bbs2-0287" title="WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Wu 2014</a>). One study of 49 stable participants with non‐CF bronchiectasis reported a link between bacterial load and airway inflammation through bronchoalveolar lavage (<a href="./references#CD001392-bbs2-0254" title="AngrillJ , AgustiC , DeCelisR , FilellaX , RanoA , ElenaM , et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. American Journal of Respiratory and Critical Care Medicine2001;164:1628‐32. ">Angrill 2001</a>). Another study in patients with COPD that included 43 participants with bronchiectasis also observed the correlation (<a href="./references#CD001392-bbs2-0263" title="HillAT , CampbellEJ , HillSL , BayleyD , StockleyRA . Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. American Journal of Medicine2000;109:288‐95. ">Hill 2000</a>). A strong evidence base from studies of patients with cystic fibrosis bronchiectasis supports this theory by reporting that antibiotic treatment during both stable and exacerbation periods resulted in reduced markers of inflammation. The disease pathophysiology is different; therefore direct comparison between these conditions is precarious (<a href="./references#CD001392-bbs2-0255" title="ChalmersJD , SmithMP , McHughBJ , DohertyC , GovanJR , HillAT . Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;186(7):657‐65. ">Chalmers 2012</a>). </p> </section> <section id="CD001392-sec-0020"> <h3 class="title" id="CD001392-sec-0020">Why it is important to do this review</h3> <p>To date, clinical research trials have described mixed results on the effectiveness of antibiotics for reducing airway inflammation and subsequent bronchiectasis (<a href="./references#CD001392-bbs2-0255" title="ChalmersJD , SmithMP , McHughBJ , DohertyC , GovanJR , HillAT . Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;186(7):657‐65. ">Chalmers 2012</a>). Some studies have suggested that antibiotic therapy had little or no effect on airway inflammation (<a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>), but others examining long‐term use of antibiotics have revealed reduced levels of myeloperoxidase (MPO) and neutrophil elastase activity in sputum (<a href="./references#CD001392-bbs2-0068" title="HillSL , MorrisonHM , BurnettD , StockleyRA . The response of patients with purulent bronchiectasis to antibiotics for four months. Quarterly Journal of Medicine1988;66(250):163‐73. ">Hill 1988</a>; <a href="./references#CD001392-bbs2-0113" title="LinHC , ChengHF , WangCH , LiuCY , YuCT , KuoHP . Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1997;155(6):2024‐9. ">Lin 1997</a>), indicating reduced airway inflammation (<a href="./references#CD001392-bbs2-0255" title="ChalmersJD , SmithMP , McHughBJ , DohertyC , GovanJR , HillAT . Short‐ and long‐term antibiotic treatment reduces airway and systemic inflammation in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;186(7):657‐65. ">Chalmers 2012</a>). The last Cochrane review update on this topic produced some evidence to suggest a small benefit can be achieved with the use of prolonged antibiotics in the treatment of bronchiectasis (<a href="./references#CD001392-bbs2-0289" title="EvansDJ , BaraAI , GreenstoneM . Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD001392.pub2] ">Evans 2007</a>), although recommendations were limited by a paucity of data. Since 2007, several trials using different types of antibiotic therapy have been published. Therefore, an update of the existing Cochrane review undertaken to examine newly published evidence on the role of prolonged antibiotic therapy in the management of non‐CF bronchiectasis is required. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001392-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001392-sec-0021"></div> <p>To determine the benefits of prolonged antibiotic therapy in the treatment of patients with bronchiectasis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001392-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001392-sec-0022"></div> <section id="CD001392-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001392-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled parallel and cross‐over trials.</p> </section> <section id="CD001392-sec-0025"> <h4 class="title">Types of participants</h4> <p>Adult and paediatric participants diagnosed with bronchiectasis by plain film chest radiograph, bronchography or high‐resolution computed tomography who reported daily sputum expectoration for at least three months were included. Studies were excluded if patients had been receiving continuous or high‐dose antibiotics immediately before the study, or if they had received a diagnosis of cystic fibrosis (CF), sarcoidosis or allergic bronchopulmonary aspergillosis. </p> </section> <section id="CD001392-sec-0026"> <h4 class="title">Types of interventions</h4> <p>Any dose of prolonged antibiotic therapy of four or more weeks versus placebo or as required treatment. </p> </section> <section id="CD001392-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD001392-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001392-list-0001"> <li> <p>Exacerbations.</p> </li> <li> <p>Hospitalisations.</p> </li> </ol> </p> </section> <section id="CD001392-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001392-list-0002"> <li> <p>Response rates.</p> </li> <li> <p>Sputum volume and purulence.</p> </li> <li> <p>Measures of lung function (e.g. forced expiratory volume in one second (FEV1)).</p> </li> <li> <p>Systemic markers of infection (e.g. leucocyte count, C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR)). </p> </li> <li> <p>Adverse events (e.g. cardiac arrhythmias, GI symptoms, hearing impairment).</p> </li> <li> <p>Deaths.</p> </li> <li> <p>Emergence of resistance to antibiotics.</p> </li> <li> <p>Exercise capacity (e.g. Six‐Minute Walk Distance (6MWD)).</p> </li> <li> <p>Quality of life (e.g. St George Respiratory Questionnaire (SGRQ)).</p> </li> </ol> </p> <p>Reporting by the trial of one of more of the outcomes listed here was not an inclusion criterion for the review. </p> </section> </section> </section> <section id="CD001392-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001392-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Trials Search Co‐ordinator for the Group. The Register contains trial reports identified through systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED) and PsycINFO, and by handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD001392-sec-0095">Appendix 1</a> for further details). We searched all records in the CAGR using the search strategy provided in <a href="http://archie.cochrane.org/sections/documents/view?document=379300090609553974%26format=REVMAN#APP-02" target="_blank">Appendix 2</a>. </p> <p>We also conducted a search of ClinicalTrials.gov (www.ClinicalTrials.gov) and the World Health Organization (WHO) trials portal (www.who.int/ictrp/en/). We searched all databases from their inception to February 2014, with no restriction on language of publication. </p> </section> <section id="CD001392-sec-0032"> <h4 class="title">Searching other resources</h4> <p>In addition, we checked the reference lists of all available primary studies and review articles to identify potentially relevant citations and made inquiries to the authors of primary studies regarding other published or unpublished trials known to them. </p> </section> </section> <section id="CD001392-sec-0033"> <h3 class="title" id="CD001392-sec-0033">Data collection and analysis</h3> <section id="CD001392-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (KH and CN) independently examined the output generated by the literature search. We obtained all potentially relevant articles and selected trials from identified studies on the basis of previously agreed inclusion criteria. Review authors described study characteristics and outcomes. </p> </section> <section id="CD001392-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (KH and CN) independently extracted data and risk of bias data from included trials and resolved conflicts by discussion with a third review author (KVC). </p> </section> <section id="CD001392-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (KH and CN) assessed each study for risk of bias for random sequence generation, allocation concealment, blinding of participants and outcome assessors, handling of missing data, selective outcome reporting and other threats to validity in the studies, in line with recommendations provided in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001392-bbs2-0262" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011</a>). We conducted a retrospective risk of bias assessment by applying the above method to all original studies included in the previous version of this review. </p> </section> <section id="CD001392-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We extracted and analysed continuous and dichotomous outcome data using standard statistical techniques with a fixed‐effect model for all studies deemed similar enough to be pooled. In the presence of significant heterogeneity, we employed a random‐effects model. </p> <p>For continuous outcomes, we calculated mean differences (MDs) with 95% confidence intervals (CIs) and pooled MDs or standardised mean differences (SMDs). For dichotomous outcomes, we calculated risk ratios (RRs) with 95% CIs. </p> <p>We performed a narrative synthesis for each of the included studies and combined all data using Review Manager software. </p> </section> <section id="CD001392-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>We included in the review a mixture of cross‐over and parallel studies with the potential for unit of analysis issues to occur. We used the generic inverse variance (GIV) method (by entering effect estimates and their standard errors) to adjust for unit of analysis errors when meta‐analysing the data, as per Section 7.7.7 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001392-bbs2-0262" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011</a>). </p> </section> <section id="CD001392-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We evaluated missing information regarding participants on an available case analysis basis, as described in Chapter 16.2.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001392-bbs2-0262" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928. ">Higgins 2011</a>). When statistics essential for analysis were missing (e.g. when group means and standard deviations for both groups were not reported) and could not be calculated from other data, we attempted to contact study authors to obtain missing data. Loss of participants that occurred before baseline measurements were obtained was assumed to have no effect on the eventual outcome data of the study. We assessed and discussed losses after baseline measurements were taken by using an intention‐to‐treat approach. </p> </section> <section id="CD001392-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity by using a combination of tests including I<sup>2</sup> statistic ≥ 50% and visual inspection of data; had 10 or more studies been included, we would have used funnel plots as well. We considered the Der‐Simonian and Laird method of analysis presented with a P value less than 0.05 as statistically significant. </p> <p>In the presence of significant heterogeneity (as per the criteria above), we re‐analysed data using both fixed‐effect and random‐effects models. </p> </section> <section id="CD001392-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to explore potential reporting biases by using a funnel plot if we were able to meta‐analyse 10 or more studies. Instead, we extrapolated on this possible risk of bias within the other bias section in the risk of bias tables. </p> </section> <section id="CD001392-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We combined data from all trials using Review Manager 5.2 software. We reported studies by using intention‐to‐treat analysis when all participants who were randomly assigned during the study were assessed, regardless of whether they received the intervention/study treatment to which they were allocated. </p> </section> <section id="CD001392-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Planned subgroups included adults versus children.</p> </section> <section id="CD001392-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct a sensitivity based on risk of bias. However, we did not do this as none of the included studies had high risk of bias for sequence generation or allocation concealment. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001392-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001392-sec-0045"></div> <section id="CD001392-sec-0046"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD001392-sec-0114" title="">Characteristics of included studies</a>, <a href="./references#CD001392-sec-0115" title="">Characteristics of excluded studies</a> and <a href="./references#CD001392-sec-0116" title="">Characteristics of studies awaiting classification</a> for additional details on 18, 202 and four studies, respectively. </p> <section id="CD001392-sec-0047"> <h4 class="title">Results of the search</h4> <p>We have provided in <a href="#CD001392-tbl-0002">Table 1</a> details of previous searches up to January 2007. Update searches from 2007 to February 2014 retrieved 249 citations. After exclusions based on title and abstract, we assessed 221 full‐text papers for eligibility. We determined that nine new studies were eligible for inclusion and hence included a total of 18 studies in this review. See <a href="#CD001392-fig-0001">Figure 1</a> for the study flow diagram. </p> <div class="figure" id="CD001392-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001392-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <div class="table" id="CD001392-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Search years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detail</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All years to January 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N citations retrieved: 447<br/> N studies included: 6 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>January 2003 to January 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No new studies identified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>January 2004 to January 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No new studies identified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>January 2005 to January 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N citations retrieved: 11<br/> N retrieved: 4<br/> N included: 3 </p> </td> </tr> </tbody> </table> </div> <p>For details on each included study, see <a href="./references#CD001392-sec-0114" title="">Characteristics of included studies</a> and the description of characteristics of included studies provided in <a href="#CD001392-tbl-0003">Table 2</a>. </p> <div class="table" id="CD001392-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Age (mean ± SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Participants (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Follow‐up (weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Int</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Cont</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Int</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Cont</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/NZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.99 ± 2.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.22 ± 2.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 ± 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 ± 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.1 ± 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.5 ± 9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/NZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 ± 5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.5 ± 13.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.9 ± 12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 ± 9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aust; Germany; Spain; Sweden; UK; USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.7 ± 11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4 ± 11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.9 ± 13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.0 ± 13.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scotland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (53‐67)‡</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (55.7‐69)‡</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1 ± 2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9 ± 2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.8 ± 9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.8 ± 9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 to 56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5 (38‐75)†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5 (38‐75)†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0 ± 8.5¶</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4 ± 10.3¶</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 ± 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 ± 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3 ± 2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.9 ± 2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int 1: 34.3; Int 2: 32.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int 1: 36; Int 2: 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* = median; † = mean and range; ‡ = median and IQR; ¶ = mean + SE.</p> </div> </div> </section> <section id="CD001392-sec-0048"> <h4 class="title">Included studies</h4> <section id="CD001392-sec-0049"> <h5 class="title">Study design</h5> <p>Sixteen of the included trials were parallel‐group studies, and two used a cross‐over design (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>). These 18 studies including international multi‐centred studies randomly assigned a total of 1157 participants and were published between 1957 and 2013. Two of these studies were conducted in the USA (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>), three in the United Kingdom (<a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>), three in Spain (<a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>), and one each in one Australia (<a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>), China (<a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>), Hong Kong (<a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>), the Netherlands (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>), New Zealand (<a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>), South Korea (<a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>) and Turkey (<a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). Three studies were conducted across multiple countries being <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a> (Australia and New Zealand), <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> (Australia and New Zealand) and the <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> study (Australia, Germany, Spain, Sweden, UK and USA). </p> </section> <section id="CD001392-sec-0050"> <h5 class="title">Participants</h5> <p>A total of 1157 participants (from n = 1627 eligible participants) were randomly assigned across the 18 studies; most were adults (n = 1009) with a mean age of 59 years. In all, 148 children participated in the three paediatric studies (<a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). Participants from all of the included studies, except <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>, <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a> and <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>, were diagnosed with non‐CF bronchiectasis, confirmed by computed tomography scan. Exclusion criteria were mentioned by all of the included studies and were explicitly described by some. </p> </section> <section id="CD001392-sec-0051"> <h5 class="title">Baseline lung function</h5> <p>Fourteen studies reported baseline lung function (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>). </p> </section> <section id="CD001392-sec-0052"> <h5 class="title">Baseline exacerbation rates or episodes</h5> <p>Seven studies adjusted baseline exacerbation rates or episodes (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>). In the <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> study, the intervention group had more frequent exacerbations (intervention n = 5 vs control n = 1), but the <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> study reported more frequent exacerbations in the control arm (intervention n = 11 vs control n = 15). Eight studies (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>) did not report baseline exacerbations. </p> </section> <section id="CD001392-sec-0053"> <h5 class="title"><i>Pseudomonas aeruginosa</i> isolate </h5> <p><a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>, <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>, <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>, <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>, <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>, <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>, <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>, <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>, <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>, <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> and <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> reported <i>Pseudomonas aeruginosa</i>. All participants as per trial protocols from <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>, <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>, <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> and <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> had positive <i>P. aeruginosa</i> growth at baseline. <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> cultured 8 of 17 participants taking amoxycillin (intervention) and 7 of 19 given placebo but also reported having 21 participants with <i>Pseudomnas</i> at baseline or during treatment. In <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>, 23 of 59 (39%) participants taking erythromycin (intervention) versus 18 of 58 (31%) given placebo had <i>P. aeruginosa</i>. <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> reported growth of <i>P. aeruginosa</i> in 6 of 43 (14%) participants taking azithromycin(intervention) and in 6 of 40 (15%) given placebo, and <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> had <i>P. aeruginosa</i> present in 7 of 16 participants taking azithromycin (intervention) and in 5 of 14 given placebo at baseline. Study authors from <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> reported that 9 of 71(13%) participants taking azithromycin (intervention) and 8 of 70 (11%) given placebo were positive for <i>P. aeruginosa</i>. <a href="#CD001392-tbl-0004">Table 3</a> provides a summary showing types of interventions and status of <i>P. aeruginosa</i>. </p> <div class="table" id="CD001392-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Types of interventions and status of Pseudomonas aeruginosa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with PA (baseline)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with PA (end of intervention)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotics</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delivery mode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Int duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up (weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/43 on intervention, 6/40 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43 on intervention, 4/40 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/16 on intervention, 5/14 on control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/16 on intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12#</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a> BLESS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/59 on intervention, 18/58 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/59 on intervention, 17/58 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45 on intervention, 0/44 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45 on intervention, 0/44 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.8 (mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> EMBRACE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/71 on intervention, 8/70 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/46 on intervention, 5/45 on placebo*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 to 56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11 on intervention, 6/10 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erthromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/17 on intervention, 7/19 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/17 on intervention, 4/19 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxycillin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int 1: penicillin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Int 2: oxytetracycline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a> ORBIT </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/20 on intervention, 22/22 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/20 on intervention, 19/22 on placebo†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/60 on intervention, 35/64 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/40 on intervention, 4/49 on placebo‡</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/30 on intervention, 30/30 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/30 on intervention§</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/37 on intervention, 37/37 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/37 on intervention, 0/37 on placebo*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/7 on intervention, 8/8 on control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/7 on intervention, 8/8 on control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ceftazidime/tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/27 on intervention, 11/30 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/13 on intervention*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gentamicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PA = <i>Pseudomonas aeruginosa</i> . *Eradicated. †At day 28. ‡Negative bacterial culture at end of intervention. §Transient disappearance of <i>Pseudomonas</i> in culture. #Actual follow‐up period was not reported. </p> </div> </div> </section> <section id="CD001392-sec-0054"> <h5 class="title">Smoking history</h5> <p>No information on smoking was available in 11 studies (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). Smoking was described variably in <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> (1 of 11 taking erythromycin and 2 of 10 given placebo were ex‐smokers), <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> (8 of 11 participants were past or present smokers), <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> (8 of 27 taking azithromycin and 8 of 30 given placebo were ex‐smokers), <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> (1% given intervention vs 6% given placebo were smokers), <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a> (10 of 59 (16.9%) and 15 of 58 (25.9%) were ex‐smokers), <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a> (1 of 20 taking ciprofloxacin was an ex‐smoker) and <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> (20 of 43 taking azithromycin and 18 of 40 given placebo were past or present smokers). </p> </section> <section id="CD001392-sec-0055"> <h5 class="title">Radiological extent of bronchiectasis</h5> <p>The radiological extent of bronchiectasis was reported in terms of the number of lobes involved by <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> (n = 15) and <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> (n = 22) (at least three lobes were involved in all participants) and <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> (12 of 17 taking amoxycillin and 10 of 19 given placebo had three or more lobes). </p> </section> <section id="CD001392-sec-0056"> <h5 class="title">Interventions</h5> <p>The length of studies varied with intervention duration and ranged from 4 to 82.8 (mean value from <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>) weeks. Antibiotics (and route of administration) assessed in the studies were tobramycin (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>: nebulised), ceftazidime (<a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>: nebulised), amoxycillin (<a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>: oral), roxithromycin (<a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>: oral), penicillin (<a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>: oral), oxytetracycline (<a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>: oral), erythromycin (<a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>: oral), clarithromycin (<a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>: oral) and azithromycin (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>: oral). All studies were placebo‐controlled with the exception of <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>, <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>, <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> and <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>, in which control groups were given usual medical care. </p> </section> </section> <section id="CD001392-sec-0057"> <h4 class="title">Excluded studies</h4> <p>We recorded reasons for exclusion of 202 studies in <a href="./references#CD001392-sec-0115" title="">Characteristics of excluded studies</a>. The most common reasons for exclusion in order of prevalence include the following: not a randomised controlled trial (n = 67), no prolonged antibiotics (n = 51), not all bronchiectasis patients (n = 37), full review not possible and drug not used in clinical practice (n = 18), not non‐CF bronchiectasis (n = 17), other reasons (n = 10) and no control group (n = 2). </p> </section> </section> <section id="CD001392-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>Full details of our risk of bias judgements can be found under the "Risk of bias" section at the end of each <a href="./references#CD001392-sec-0114" title="">Characteristics of included studies</a> table and in <a href="#CD001392-fig-0002">Figure 2</a>. Overall, the methodological quality of included studies was good. Two independent review authors (KH and CN) reached agreement when assessing study quality. </p> <div class="figure" id="CD001392-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001392-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001392-sec-0059"> <h4 class="title">Allocation</h4> <p>Generation of the randomisation sequence was considered adequate in five studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) and unclear in 13 studies (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>). </p> <p>The method of allocation concealment was determined to be adequate in four studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) and unclear in 13 studies (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). However, <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> was assessed to have high risk of bias for allocation concealment. </p> </section> <section id="CD001392-sec-0060"> <h4 class="title">Blinding</h4> <p>Risk associated with participant blinding was deemed to be low when the study provided identical tablets or visually identical liquid and packaging and the same follow‐up for participants. Adequate blinding of assessors was reported on the basis of information provided by study authors, such as a clear and well‐defined study protocol, central or third party allocation of assessors and treating doctors and the same follow‐up, measurements and tests provided for participants from both arms of the study. </p> <p>Risk of detection bias due to inadequate blinding of outcome assessors has been judged as high in five studies (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>) and unclear in five trials (<a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>), with no specific details provided in the trial reports. Although <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> was assessed to have high risk of bias for blinding of participants, risk was unclear for blinding of outcome assessors. <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>, <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>, <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>, <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>, <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>, <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>, <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> and <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> were deemed to have low risk of bias. </p> </section> <section id="CD001392-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>Low risk of bias was assessed in eight studies (<a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>). We report high risk of attrition bias in <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> and <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> and unclear risk in eight studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). </p> </section> <section id="CD001392-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Selective reporting (reporting bias) was considered to introduce low risk in eight studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>); however it was determined to bring high risk in five studies (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). The remaining five studies (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>) were identified to have unclear risk for reporting bias. </p> </section> <section id="CD001392-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Other potential sources of bias were not identified in nine studies (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>), but this could not be adequately assessed in eight studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). High risk of the other potential sources of bias was identified in <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>. </p> </section> </section> <section id="CD001392-sec-0064"> <h3 class="title" id="CD001392-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD001392-tbl-0001"><b>Summary of findings for the main comparison</b> Prolonged antibiotics for purulent bronchiectasis in children and adults</a> </p> <section id="CD001392-sec-0065"> <h4 class="title">Primary outcomes</h4> <section id="CD001392-sec-0066"> <h5 class="title">1. Exacerbations</h5> <p>Fifteen of 18 included studies with 956 participants reported data on exacerbations. A total of 13 studies (with 884 participants) could be pooled in a meta‐analysis using generic inverse variance, with 10 reporting dichotomous data (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) and three continuous data (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>), producing statistically significant benefits in favour of the antibiotic arm (odds ratio (OR) 0.31; 95% confidence interval (CI) 0.19 to 0.52; I² = 51%; P value &lt; 0.00001; <a href="#CD001392-fig-0003">Figure 3</a>) and reporting similar results for the sensitivity analysis using a fixed‐effect model (P value &lt; 0.0001; <a href="./references#CD001392-fig-0020" title="">Analysis 2.1</a>). Data from two cross‐over studies (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>) involving 12 and 60 participants, respectively, were limited to individual studies. <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> did not detect a significant difference between treatments in terms of mean exacerbations per participant (mean difference (MD) ‐0.4, P value = 0.32) but found a significant difference in the mean number of admissions in favour of tobramycin (MD ‐0.6, P value = 0.03). <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>, which included 12 participants, reported fewer exacerbations requiring antibacterial therapy in the azithromycin phase than in the control phase (5 events vs 16, P value = 0.019). Exacerbation was not reported by three trials (<a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). For absolute treatment differences, 55 of 100 people in the control group had one or more exacerbations over 1.5 to 24 months compared with 32 (95% CI 25 to 41) of 100 given prolonged antibiotics (<a href="#CD001392-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD001392-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), outcome: 1.1 Exacerbations." data-id="CD001392-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), outcome: 1.1 Exacerbations. </p> </div> </div> </div> <div class="figure" id="CD001392-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Absolute treatment differences for exacerbations with events occurring in 546 per 1000 in the control arm and in 271 per 1000 (95% CI 126 to 385) people on the intervention." data-id="CD001392-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Absolute treatment differences for exacerbations with events occurring in 546 per 1000 in the control arm and in 271 per 1000 (95% CI 126 to 385) people on the intervention. </p> </div> </div> </div> <section id="CD001392-sec-0067"> <h6 class="title">Number of courses of antibiotics</h6> <p>Supplemental antibiotic use for pulmonary or non‐pulmonary exacerbations was reported in 14 studies including 1021 participants (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>). Three of the 18 studies analysed did not report on supplementary antibiotic courses during the study treatment phase (<a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). </p> <p>Supplemental antibiotic prescription and use correlated with identified exacerbations; however all but two studies failed to indicate duration or number of courses (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>). <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> recorded that two participants required treatment with sparfloxacin (200 mg daily for 10 days), and <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> mentioned use of supplemental non‐macrolide antibiotics for two weeks following pulmonary exacerbations. </p> <p>The two cross‐over trials (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>) showed that use of supplemental antibiotics correlated with infective pulmonary exacerbations, with less use reported in the treatment arm than in the placebo arm. These trials did not report the number or duration of courses. The number of supplementary antibiotic courses taken during the study treatment phase of the <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> study was reported to be related to the number of courses taken during the previous year rather than to the allocated treatment regimen. </p> </section> </section> <section id="CD001392-sec-0068"> <h5 class="title">2. Hospitalisations</h5> <p>Seven parallel studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) with 13 of 322 intervention participants and 28 of 321 placebo participants reported hospitalisations, with a non‐statistically significant result in favour of the intervention (OR 0.40, 95% CI 0.14 to 1.11; P value = 0.08; I² = 36%; <a href="./references#CD001392-fig-0008" title="">Analysis 1.2</a>). The sensitivity analysis using the fixed‐effect model did however produce statistical significance (P value = 0.02; <a href="./references#CD001392-fig-0021" title="">Analysis 2.2</a>). <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>, a cross‐over trial with 30 participants, reported improvement in the number of admissions per participant using mean ± SD (0.15 ± 0.37 taking intervention vs 0.75 ± 1.16 given placebo). In terms of absolute treatment differences, 9 of 100 people in the control group had one or more hospitalisations over 1.5 to 24 months compared with 4 (95% CI 2 to 8) of 100 given prolonged antibiotics (<a href="#CD001392-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD001392-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Absolute treatment differences for hospitalisations with events occurring in 87 per 1000 in the control arm and in 37 per 1000 (95% CI 13 to 96) on the intervention." data-id="CD001392-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Absolute treatment differences for hospitalisations with events occurring in 87 per 1000 in the control arm and in 37 per 1000 (95% CI 13 to 96) on the intervention. </p> </div> </div> </div> </section> </section> <section id="CD001392-sec-0069"> <h4 class="title">Secondary outcomes</h4> <section id="CD001392-sec-0070"> <h5 class="title">1. Response rates</h5> <p>A significant treatment effect was noted following meta‐analysis for clinical response rates in two studies (OR 3.37, 95% CI 1.60 to 7.09; n = 110; P value = 0.001; <a href="./references#CD001392-fig-0009" title="">Analysis 1.3</a>). In spite of slightly differing definitions of response between studies (<a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> reported physician assessment of diary cards; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> reported physician assessment of overall medical condition), no heterogeneity was observed. <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> reported no significant differences in disease progression (3/17 vs 4/19 participants in the antibiotic and control groups, respectively). Participant‐reported symptoms were measured by the Lower Respiratory Tract Infection Visual Analogue Scale (LRTI VAS) in the <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> study, which showed a larger decrease in total score (indicating fewer symptoms) among participants receiving the intervention compared with control participants at the end of the treatment period (six months; P value = 0.047). </p> </section> <section id="CD001392-sec-0071"> <h5 class="title">2. Sputum volume and purulence</h5> <p>Sputum volume and purulence were reported in 15 studies including 975 participants, one of which was a cross‐over study (<a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). As these results were variably reported, a meta‐analysis was not performed. Of these studies, nine recorded data for both sputum volume and purulence (<a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>). Four of the 15 studies reported on sputum purulence alone (<a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>) and one study reported solely on sputum volume (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>). </p> <p>Of studies reviewing populations of children, <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> reported on sputum purulence via a sputum colour chart (Bronkotest). However, sputum characteristics were reported as a definition of an exacerbation rather than as a distinct secondary outcome in itself, and no follow‐up results were mentioned thereafter. <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a> on the other hand reported a significant difference in sputum volume with improvement in the treatment arm of the study. Sputum purulence was measured via total cell number and neutrophil ratios in bronchoalveolar lavage, and also showed a significant improvement in the treatment arm of the study.Both parallel and cross‐over trials showed a greater reduction in sputum volume and purulence in the long‐term antibiotic group than in the placebo group. </p> <p>Sputum diary cards were used in one study on 38 participants (<a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>). Independent assessment of diary cards in the <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> study revealed improvement in sputum colour and/or reduction in reported sputum volume, which persisted throughout the post‐treatment phase in three intervention participants. Symptomatically, the prolonged antibiotic course was considered successful, as judged by independent assessment of diary card data and in the opinion of participants (<a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>). </p> <p><a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a> reported significantly lower sputum purulence scores in the antibiotic group compared with the placebo group (1.39 ± 0.6 vs 2.17 ± 0.72; P value &lt; 0.01). <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a> reported that sputum production was significantly less in the antibiotic group (P value = 0.0001). <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> reported no significant differences in median sputum volume production between treatments (25 mL vs 24 mL). A greater reduction in 24‐hour purulent sputum volume was noted in the <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> study between exacerbations during the study treatment phase in the amoxycillin group (median 20% of pre‐treatment volume) compared with the placebo phase (88% of pre‐treatment volume; P value = 0.008), although concentrations of <i>Haemophilus</i> spp. in sputum between exacerbations were similar in the two groups. However, no differences between groups were observed in the post‐treatment phase. The reduction in 24‐hour total sputum volume between acute exacerbations during the study treatment phase was also significantly greater in the amoxycillin group (42% of pre‐treatment values) than in the placebo group (81%; P value = 0.04), although in the post‐treatment phase no differences were observed between groups. <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> reported that participants in the erythromycin group (n = 11) but not in the placebo group (n = 10) had significantly improved 24‐hour sputum volume after eight weeks (P value &lt; 0.05). </p> </section> <section id="CD001392-sec-0072"> <h5 class="title">3. Measures of lung function</h5> <p>Lung function was reported in 16 studies with a total number of 990 randomly assigned participants (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). Most studies reported a combination of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC); however some studies reported FEV1 alone. As lung function was variably reported, only limited data were available for meta‐analysis. The only available pooled effect estimates showed no evidence of any effect for FEV1% predicted (standardised mean difference (SMD) ‐0.12, 95% CI ‐0.34 to 0.10), change in FEV1 (SMD ‐0.07, 95% CI ‐0.84 to 0.70) and absolute FEV1 (SMD ‐0.36, 95% CI ‐1.03 to 0.30; <a href="./references#CD001392-fig-0010" title="">Analysis 1.4</a>). A sensitivity analysis based on the fixed‐effect model also found no evidence of any effect (<a href="./references#CD001392-fig-0022" title="">Analysis 2.3</a>). </p> <p>Among the adult population, 10 parallel studies showed no evidence of any effect on lung function measurements in intervention and placebo groups at the end of the trial (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>). <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> showed statistically significant improvement in FEV1 and FVC at the end of the trial period in the intervention group versus the placebo group (P value = 0.047 and P value = 0.02, respectively). However, these results were not maintained over the six months after cessation of the intervention. <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a> showed a significant arrest in the decline of FEV1 among participants receiving erythromycin during the treatment period (P value = 0.04). </p> <p>Two cross‐over trials including 72 participants (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>) reported no evidence of any effect on lung function between intervention and placebo groups at the end of the treatment period. Long‐term azithromycin administration during <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> demonstrated no significant changes in FEV1 (1.28 ± 0.55 L vs 1.20 ± 0.46 L (azithromycin) vs 1.18 ± 0.51 L (control); P value = 0.153) or FVC (2.25 ± 0.72 L vs 2.22 ± 0.60 L (azithromycin) vs 2.12 ± 0.62 L (control); P value = 0.440). Non‐significant changes (%) in these measures between treatment groups (tobramycin vs placebo) were also noted in <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> (FEV1 –3.50, 95% CI –5.95 to –1.02 vs –1.20, 95% CI –4.38 to –1.98; P value = 0.240; FVC –5.45, 95% CI –8.03 to –2.87 vs –1.30, 95% CI –4.88 to –2.28; P value = 0.056). </p> <p>The two studies involving children (<a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>) reported no evidence of any effect on lung function between antibiotic and placebo groups at the end of the trials (total n = 126). <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a> showed no evidence of an effect in FEV1% between treatment groups (clarithromycin vs placebo); however, investigators did report improvement in forced expiratory flow at 25% to 75% (FEF25‐75%) in the clarithromycin group at the beginning of the study and at month three (P value = 0.015). Similarly, <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> showed no evidence of any effect on mean predicted FEV1% between antibiotic and placebo groups (84.7 (12.9) vs 81.0 (18.3); P value = 0.38). However, FEV1 data were incomplete, as spirometry was conducted only in participants older than six years. </p> </section> <section id="CD001392-sec-0073"> <h5 class="title">4. Systemic markers of infection</h5> <section id="CD001392-sec-0074"> <h6 class="title">Leucocyte count</h6> <p>A total of 402 participants ‐ 201 participants taking intervention versus 201 given placebo ‐ were measured for leucocyte counts in six studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>). <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a> (n = 13 taking roxithromycin, n = 12 given placebo), <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> (n = 17 taking amoxycillin, n = 19 given placebo), <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> (n = 30 on both arms, cross‐over trial), <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> (n = 27 taking intervention, n = 30 given placebo) and <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> (n = 43 taking azithromycin, n = 40 given placebo) reported no changes in both arms. However, <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> with 141 participants (n = 71 taking azithromycin, n = 70 given placebo) favoured the intervention (P value = 0.013). A meta‐analysis of three studies with 165 participants was possible but produced no evidence of any effect for the primary random‐effect analysis (MD ‐0.39, 95% CI ‐0.87 to 0.09; <a href="./references#CD001392-fig-0011" title="">Analysis 1.5</a>) and the sensitivity analysis (<a href="./references#CD001392-fig-0023" title="">Analysis 2.4</a>). </p> </section> <section id="CD001392-sec-0075"> <h6 class="title">C‐reactive protein (CRP)</h6> <p>Six studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) with 552 participants (276 in the intervention arm vs 276 in the placebo arm) reported on CRP. As variable reporting methods were used, we were unable to perform a meta‐analysis of all data. <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> measured the change in serum CRP levels and leucocyte counts seen in 83 participants (43 taking azithromycin vs 40 given placebo) and showed no significant differences between treatment groups (intervention median 5.0, interquartile range (IQR) 2 to 11.3 mg/dL; control median 4.5, IQR 2 to 15.3 mg/dL). <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> favoured intervention with 57 participants (27 given intervention and 30 placebo). <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> reported on 141 participants (71 taking azithromycin and 70 given placebo) and favoured intervention (P value = 0.006). <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> reported improvement in the change from baseline for 20 participants (16 taking azithromycin and 14 given placebo). In the <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> study, 124 participants (60 given intervention and 64 placebo) showed benefit in favour of the intervention, but this finding was not statistically significant (P value = 0.173). <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a> reported no effect on CRP among 54 participants taking erythromycin and 50 given placebo. </p> </section> <section id="CD001392-sec-0076"> <h6 class="title">Erythrocyte sedimentation rate (ESR)</h6> <p>Three studies with 128 participants (<a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>) reported using ESR as a marker for infection. Two of these studies could be pooled in a meta‐analysis, producing no evidence of any effect in the primary analysis (MD ‐2.47, 95% CI ‐9.76 to 4.82; <a href="./references#CD001392-fig-0012" title="">Analysis 1.6</a>) or in the sensitivity analysis (<a href="./references#CD001392-fig-0024" title="">Analysis 2.5</a>). <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>, a cross‐over trial, found no differences between intervention and control groups (n = 30), and the <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> study, with 16 participants given intervention and 14 acting as controls, reported a change from baseline (intervention ‐14 (4) vs control ‐9 (12)). The ESR in the amoxycillin group of the <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> study (n = 13 to 17) decreased slightly during treatment but did not fall in the placebo group (n = 11 to 18; P value &lt; 0.05). </p> </section> </section> <section id="CD001392-sec-0077"> <h5 class="title">5. Adverse events</h5> <p>Adverse events were reported variably in 15 studies with 683 participants (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>), and when possible, meta‐analysis was performed for each of the reported adverse events (<a href="./references#CD001392-fig-0013" title="">Analysis 1.7</a>). Eleven studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>) reported that 39 of 358 participants in the intervention arm and 43 of 325 participants in the placebo arm withdrew from the trials because of intolerable or severe adverse effects. No significant difference was observed when these events were pooled (OR 0.91, 95% CI 0.56 to 1.49; N = 683; <a href="./references#CD001392-fig-0013" title="">Analysis 1.7</a>). </p> <p>Four studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>) reported on diarrhoea. Three parallel studies reported that the intervention increased risk of diarrhoea in 24 of 136 participants given antibiotic versus 6 of 95 given placebo (n = 231) (OR 3.33, 95% CI 1.50 to 7.37; P value = 0.003; <a href="./references#CD001392-fig-0013" title="">Analysis 1.7</a>). </p> <p>Bronchospasm was reported in three studies (<a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>) and wheeze in two studies (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>). <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> had 3 of 30 participants reporting bronchospasm whilst nebulised with tobramycin. <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> and <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> reported that 10 of 92 participants given intervention and 5 of 97 given placebo had bronchospasm (OR 2.19, 95% CI 0.76 to 6.33; P value = 0.15, I² = 21%; <a href="./references#CD001392-fig-0013" title="">Analysis 1.7</a>). <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> reported that 6 of 37 participants taking tobramycin and 0 of 37 given placebo had wheeze (OR 8.56, 95% CI 1.63 to 44.93; P value = 0.01), and 12 of 37 participants taking tobramycin and 3 of 37 given placebo had worsening of dyspnoea. However, <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> reported statistically significant improvement in dyspnoea with 16 participants taking azithromycin and 14 given placebo (P value &lt; 0.05). </p> <p>Chest pains/palpitations were reported by <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> using oral azithromycin, <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> using nebulised tobramycin and <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a> using oral erythromycin (8 of 139 participants given intervention vs 1 of 135 given placebo; OR 5.21, 95% CI 1.35 to 20.14; P value = 0.02). Four studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> using oral azithromycin, <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> using oral amoxycillin, <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a> using inhaled ciprofloxacin, <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a> using oral erythromycin) with 15 of 138 participants given intervention and 13 of 137 placebo reported nausea (OR 1.20, 95% CI 0.54 to 2.67; P value = 0.66, I² = 37%). </p> <p>No significant differences between treatments were reported for fatigue (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>), haemoptysis (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>), fever (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>) or increased sputum (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>). In addition to diarrhoea, which was the most common adverse event reported in the <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a> study, anorexia, nausea, vomiting, flatulence and epigastric discomfort were also reported in order of frequency. Other recorded adverse events in this study included swelling of the foot accompanied by a rash that lasted a week, which developed eight weeks after the start of treatment with penicillin; paraesthesiae of both hands lasting a few weeks, which occurred 16 weeks after the start of oxytetracycline; and joint pain, which was reported to occur the day after administration of lactose capsules (<a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>). No participants withdrew from the <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a> study. <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> reported that the most common adverse events in this trial were non‐pulmonary infections (71 of 112 events in the azithromycin group vs 132 of 209 in the placebo group) and bronchiectasis‐related events (episodes or investigations; 22 of 112 events in the azithromycin group <i>vs</i> 48 of 209 in the placebo group). However, study drugs were well tolerated and no serious adverse events were attributed to the intervention. Authors of the <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> study reported that none of the participants given erythromycin experienced haemoptysis during the study period. </p> <p>Diarrhoea was the most common treatment‐related adverse event reported in the <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> cross‐over study, with 3 of 12 participants (25%) reporting it during the intervention period. Study authors did not mention any episodes of diarrhoea occurring during the usual care period. One participant's dose of azithromycin was changed to the alternative thrice‐weekly regimen, which was reported to improve diarrhoea. The single participant who dropped out of the study had reported diarrhoea during a previous visit. No other serious or severe treatment‐related adverse events were reported (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>). </p> </section> <section id="CD001392-sec-0078"> <h5 class="title">6. Deaths</h5> <p>No significant difference in mortality (OR 1.48, 95% CI 0.28 to 7.85; n = 595) was noted amongst the seven studies that reported on this outcome (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>); n = 595; <a href="./references#CD001392-fig-0014" title="">Analysis 1.8</a>). The two deaths reported in the intervention arm from <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> were unexpected and were due to previously undiagnosed metastatic colorectal cancer and myocardial infarction. In <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>, a cross‐over trial, 5 of 30 participants died from respiratory failure during study periods. Investigators did not report the phase of the study in which these deaths occurred. </p> </section> <section id="CD001392-sec-0079"> <h5 class="title">7. Emergence of resistance to antibiotics</h5> <p>Nine studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) with a total of 571 participants reported this outcome. As a result of the different types of results presented, data from only six studies (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) with 431 participants were used for the meta‐analysis. Drug resistance in 36 of 220 participants taking antibiotic and in 10 of 211 participants given placebo or standard therapy favoured the placebo or standard therapy group (OR 3.48, 95% CI 1.20 to 10.07; P value = 0.02; <a href="./references#CD001392-fig-0015" title="">Analysis 1.9</a>) with modest heterogeneity (I² = 29%); similar but more significant results were obtained with the sensitivity analysis (P value = 0.006; <a href="./references#CD001392-fig-0025" title="">Analysis 2.6</a>). <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> detected no resistance at the end of the study. </p> <p>Resistance patterns were comparable between groups at baseline for the <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> study (35% macrolide resistance in eight participants in the azithromycin group vs 27.5% in nine participants in the placebo group). During treatment, 53 of 60 pathogens (88%) tested for sensitivity in 20 participants in the azithromycin group became macrolide resistant, compared with 29 of 112 pathogens (26%) in 22 participants in the placebo group (P value = 0.001). Macrolide‐resistant commensal oropharyngeal streptococci were reported to be significantly increased in the <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a> study with erythromycin therapy (median change 27.7%, IQR 0.04% to 41.1%) compared with placebo (median change 0.04%, IQR ‐1.6% to 1.5%; difference 25.5%, IQR 15.0% to 33.7%; P value &lt; 0.001). In the <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> study, tobramycin‐resistant <i>P. aeruginosa</i> strains developed resistance in 11% of intervention participants compared with 3% of placebo participants, although this difference was not significant. Two participants developed resistance during the tobramycin period of the <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> study. Bacteria persisted in both participants until months two and three of the placebo period, and two additional participants had <i>P. aeruginosa</i> strains isolated during the second period of placebo treatment. The frequency and emergence of resistance did not differ significantly during the second period of placebo treatment. Other organisms were also monitored, with <i>Alcaligenes xylosoxidans</i> and <i>Streptococcus pneumoniae</i> identified in sputum cultures of two participants during the intervention treatment period, and with <i>Acinetobacter</i> spp and <i>Stenotrophomona maltophila</i> identified in two participants during the treatment period (<a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>). </p> <p>The <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> study also reported on emergence of resistance to gentamicin, which occurred with similar frequency in the two study arms (three amoxycillin and two placebo participants). No significant increase in resistance of <i>P. aeruginosa</i> isolates to ciprofloxacin was observed in the <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a> study, and likewise in the <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a> study, with no differences between groups observed. </p> <p>In terms of absolute treatment differences, 5 of 100 people in the control group had emergent antibiotic resistance over 1.5 to 24 months, compared with 15 (95% CI 8 to 27) of 100 in the prolonged antibiotics arm (<a href="#CD001392-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD001392-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Absolute treatment differences for emergence of antibiotic resistance with events occurring in 47 per 1000 in the control arm and in 148 per 1000 (95% CI 56 to 334) on the intervention." data-id="CD001392-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Absolute treatment differences for emergence of antibiotic resistance with events occurring in 47 per 1000 in the control arm and in 148 per 1000 (95% CI 56 to 334) on the intervention. </p> </div> </div> </div> <section id="CD001392-sec-0080"> <h6 class="title">Bacterial colonisation</h6> <p>A total of 15 studies with 809 participants (403 given intervention and 406 placebo) reported on this outcome (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). Given the expected nature of a trial including participants with multiple organisms from recurrence/regrowth/colonisation/active infection, a meta‐analysis was not performed. In the <a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> study, the microbiological profile did not differ significantly between groups at baseline or after 52 weeks of treatment. A total of 437 sputum samples were cultured for microbiology; this yielded one or more pathogens on 339 occasions. <i>Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, Moraxella catarrhalis</i> and <i>Haemophilus parainfluenzae</i> were most frequently encountered, together accounting for 87% of the total number of pathogens. All participants with <i>Haemophilus influenzae</i> , <i>Pseudomonas aeruginosa</i> and <i>Aspergillus</i> at baseline from the <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> study became culture negative after taking azithromycin for three months; however, study authors did not report the change in bacterial isolates in the placebo arm. <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a> reported no differences between the two groups for emergence of new sputum pathogens at any time after the start of erythromycin; however, eradication of sputum pathogens occurred in more erythromycin‐treated participants (n = 17 (30.4%) vs n = 6 placebo participants (10.9%); OR 3.6, 95% CI 1.3 to 10.6; P value = 0.01). <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a> also reported on new pathogens isolated from 12 participants given placebo and 9 taking ciprofloxacin. <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> reported that 6 of 46 participants taking azithromycin cultured new organisms, along with 10 of 45 participants given placebo. Disappearance of <i>P. aeruginosa</i> in sputum was observed in four participants taking tobramycin and in four participants given placebo in <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>;however, this cross‐over study was transient and <i>P. aeruginosa</i> re‐grew after a mean time of three months. Examination of individual microbiological responses among participants in the <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> study showed that one‐third (13 of 37) of tobramycin‐treated individuals had <i>P. aeruginosa</i> eradicated from their sputum. Twelve of these 13 participants were assessed as having an improved medical condition at week 6, and an additional third (12 of 37) showed a reduction of at least 2 log10 in <i>P. aeruginosa</i> density at week 4. Nine of these 12 participants were assessed as improved. The last third (12 of 37) of tobramycin‐treated participants had no microbiological response, and 10 of these individuals were not improved. In contrast, 33 of 35 (94%) participants given placebo had no microbiological response, and only 2 of 35 (6%) had a greater than 2 log10 decrease in <i>P. aeruginosa</i> density. <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> reported that five of seven individuals taking ceftazidime and tobramycin and six of eight given placebo cultured <i>P. aeruginosa</i>. In the <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> study, <i>Pseudomonas aeruginosa</i> and <i>Haemophilus influenzae</i> were isolated from the sputum in 10 participants and 1 participant taking erythromycin, respectively, and <i>Pseudomonas aeruginosa</i> , <i>Haemophilus influenzae</i> , <i>Klebsiella pneumoniae</i> and <i>Escherichia coli</i> were isolated in the sputum of six, two, one and one participants given placebo, respectively. <a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> with 38 participants reported <i>Haemophilus influenzae</i> , <i>P. aeruginosa</i> and <i>Staphylococcus aureus</i> at baseline and subsequently several gram‐negative bacilli but concluded that no important changes in bacterial flora were observed in either group. </p> </section> </section> <section id="CD001392-sec-0081"> <h5 class="title">8. Exercise capacity</h5> <p>Exercise capacity was reported in four studies (<a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) and was objectively assessed in 365 participants using the six‐minute walk test (6MWT). Three of these studies (<a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) reported no statistically significant differences in the 6MWT between intervention and placebo groups at the end of the intervention period. <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> reported no statistically significant differences in either group until month 12 of the trial, when improvement in exercise capacity was noted (mean 510 m, 95% CI 350 to 690 vs mean 415 m, 95% CI 267.5 to 530; P value = 0.03). These effects were not sustained at follow‐up. A meta‐analysis of two studies produced no evidence of any effect during primary analysis (SMD 0.18, 95% CI ‐0.22 to 0.58; <a href="./references#CD001392-fig-0016" title="">Analysis 1.10</a>) or sensitivity analysis (<a href="./references#CD001392-fig-0026" title="">Analysis 2.7</a>). </p> </section> <section id="CD001392-sec-0082"> <h5 class="title">9. Quality of life</h5> <p>Quality of life measure as measured on the St George Respiratory Questionnaire (SGRQ) was reported in 10 studies involving 667 participants (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>). Six of these studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>) demonstrated significant improvement in quality of life among participants with bronchiectasis who were given long‐term antibiotic treatment when compared with those given placebo. <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> reported clinically and statistically significant changes in quality of life in the antibiotic group (‐7.9 ± 3.1 vs 4.1 ± 3.8; P value &lt; 0.05) but no difference in SGRQ scores at six months. A meta‐analysis on total SGRQ scores from five parallel trials with 161 participants given intervention and 154 controls found a non‐statistically significant benefit favouring the intervention (MD ‐2.75, 95% CI ‐7.08 to ‐1.57; I² = 67%). On sensitivity analysis and re‐evaluation based on a fixed‐effect model, results remained non‐statistically significant (P value = 0.06; <a href="./references#CD001392-fig-0027" title="">Analysis 2.8</a>). Following re‐analysis based on the random‐effects model, results were no longer statistically significant (MD ‐3.71, 95% CI ‐9.84 to 2.41; I<sup>2</sup> = 90%; <a href="./references#CD001392-fig-0017" title="">Analysis 1.11</a>). </p> <p>Among the cross‐over studies, <a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> reported that 82% of participants receiving long‐term antibiotics had improved quality of life; however, formal objective measures were not employed. On the other hand, <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> showed no significant differences in quality of life (via SGRQ) between treatment and placebo arms at the end of the trial (mean –0.90 ± 3.93 vs –0.83 ± 6.89). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001392-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001392-sec-0083"></div> <section id="CD001392-sec-0084"> <h3 class="title" id="CD001392-sec-0084">Summary of main results</h3> <p>The primary aim of this review was to assess the effects of prolonged antibiotic therapy in adults and children with non‐cystic fibrosis bronchiectasis. We reviewed the evidence from 18 trials (1162 participants) between 1957 and 2013. Our primary outcome, exacerbation, was reported differently by 15 studies involving 925 participants and was significantly reduced by the intervention. However, the baseline exacerbation rate was adjusted (by individual study authors) in 7 (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>) out of 18 trials. Other influential factors such as <i>Pseudomonas</i> colonisation, smoking history and lobar involvement were variably reported and adjusted. All participants from five studies (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>) had <i>Pseudomonas aeruginosa</i> at baseline. The effect of prolonged antibiotic therapy on hospitalisation was favourable across six of seven studies with 643 participants (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>; <a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>) (<a href="./references#CD001392-fig-0008" title="">Analysis 1.2</a>), although results were not statistically significant. The baseline rate of hospitalisation for these studies was not described adequately, limiting the reliability of change scores from baseline. Participants included in this review were drawn from diverse populations. It does not necessarily follow that patients with differing anatomical distribution or aetiologically distinct underlying diseases or baseline characteristics will respond in a homogenous way to the same intervention. No significant effect on mortality, exercise capacity, lung function or quality of life was reported. However, follow‐up plans of the included studies ranging from 4 to 96 weeks suggest that the effect on mortality may not be conclusive. </p> </section> <section id="CD001392-sec-0085"> <h3 class="title" id="CD001392-sec-0085">Overall completeness and applicability of evidence</h3> <p>Despite an extensive literature search and relatively high burden of disease in the community, only 18 studies met the inclusion criteria of this review. The primary aim of this review was to address the possible benefit of prolonged antibiotic therapy for individuals with non‐cystic fibrosis bronchiectasis. </p> <p>The trials were of differing duration. We arbitrarily chose a cutoff of four weeks of treatment for eligibility because this duration was longer than the standard 7 to 10 day course of treatment traditionally provided for uncomplicated exacerbations. Furthermore, long‐term use of antibiotics was defined as use of this treatment with a prophylactic intent in patients at a chronic stable phase (i.e. not for exacerbations). The studies reported by <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> (four weeks), <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> (four weeks), <a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> (12 weeks), <a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a> (12 weeks) and <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> (eight weeks) were probably too brief to allow firm conclusions about disease‐modifying effects. </p> <p>Inclusion of six trials using inhaled antibiotics (<a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a>; <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a>) is also worthy of consideration. The mechanism of action of inhaled antibiotics may differ from that of antibiotics given by the oral route; however, increased withdrawals due to severe adverse events or intolerable effects were noted in both study arms when compared with oral interventions. </p> <p>In conclusion, 15 trials in this review demonstrate a trend supporting use of prolonged antibiotics in the management of bronchiectasis with significant risk of emergence of drug resistance. Therefore, appropriate patient selection is essential. The intervention was safe and tolerated by study participants, particularly when the oral route was used. Trials exhibited significant shortcomings, particularly in terms of study duration, baseline exacerbation, hospitalisation and bacterial colonisation/isolation, hence further research is required. These new studies should incorporate methods allowing separate study of specific issues such as <i>Pseudomonas aeruginosa</i> colonisation and drug resistance at individual and community levels. </p> </section> <section id="CD001392-sec-0086"> <h3 class="title" id="CD001392-sec-0086">Quality of the evidence</h3> <p>The overall quality of studies included in this review was moderate. Most included studies reported that they blinded assessors and participants from allocation; however not enough information was provided for this assessment. In addition, information was insufficient to assess attrition bias, especially with reporting bias (<a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a>; <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a>; <a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>; <a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a>). Small sample sizes further limited the ability of study authors to draw reliable conclusions regarding efficacy, tolerability and safety. </p> <p>Attempts to outline a mechanism for clinical effects (other than sputum volume, purulence, cultures and resistance patterns) were limited to the studies reported by <a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> and <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a>. In the former investigation, no change was seen in sputum cytokines or leukotrienes despite improvements in lung function and sputum volume. <a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> showed a reduction in airway responsiveness and suggested that this might have occurred through indirect effects on airway inflammation. </p> <p>In general, the trials suggest that long‐term antibiotics in bronchiectasis are an effective intervention for reducing sputum volume and purulence, but they have a very limited impact on the natural history of the condition. However, several important issues related to this review weaken the power of review authors to draw final conclusions; these will be addressed in turn. </p> </section> <section id="CD001392-sec-0087"> <h3 class="title" id="CD001392-sec-0087">Potential biases in the review process</h3> <p>No significant biases were anticipated or were found to occur during the review process. Criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> were strictly followed to limit the potential for bias during screening, data extraction and analyses of included studies. Risk of bias was assessed independently by two review authors (KH and CN), who resolved conflicts by discussion with a third review author (KVC). We contacted the corresponding author of two included studies (<a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a>; <a href="./references#CD001392-bbs2-0012" title="ChenAC‐H , MartinMM , BurrL , HasnainSZ , LourieR , BowlerSD , et al. Clinical benefits of long‐term, low‐dose erythromycin in bronchiectasis are not due to anti‐inflammatory effects. American Thoracic Society International Conference; 2013 May 17‐22; Philadelphia. 2013. SerisierD , MartinM , McGuckinM , LourieR , ChenA , BrainB , et al. Effect of long‐term, low‐dose erythromycin on pulmonary exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;309(12):1260‐6. SerisierDJ , BowlerSD , McGuckinM , ChenA , LourieR , MartinML . The Bronchiectasis and Low‐dose Erythromycin Study (BLESS). American Journal of Respiratory and Critical Care Medicine2012;185:A6862. SerisierDJ , MartinM . Long‐term, low‐dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respirology2011;105(6):946‐9. ">Serisier 2013a BLESS</a>; <a href="./references#CD001392-bbs2-0013" title="BruinenbergP , SerisierD , BlanchardJ , CipollaD , GondaI . Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. European Respiratory Society 20th Annual Congress; 2010 Sep 18‐22; Barcelona. 2010. CipollaDC , GondaI , SerisierD , BruinenbergP . Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2011; Vol. 24, issue 3:A27. SerisierD , KolbeJ , GrevilleH , GondaI , BruinenbergP . Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non‐cystic fibrosis bronchiectasis. American Thoracic Society International Conference; 2011 May 13‐18; Denver. Denver, Colorado, 2011; Vol. 183:A4866. SerisierDJ , BiltonD , DeSoyzaA , ThompsonPJ , KolbeJ , GrevilleHW , et al. Inhaled, dual release liposomal ciprofloxacin in non‐cystic fibrosis bronchiectasis (ORBIT‐2): a randomised, double‐blind, placebo‐controlled trial. Thorax2013;68:812‐7. SerisierDJ , ThompsonPJ , GrevilleH , KolbeJ , BruinenbergPR . Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non‐cystic fibrosis (CF) bronchiectasis (BE). American Thoracic Society International Conference; 2011 May 13‐18; Denver. 2011; Vol. 28:334s [1928]. ">Serisier 2013b ORBIT</a>) and the authors of the three initially unclassified citations to ask for raw data and clarification of methodological techniques. The review authors of this meta‐analysis have reported no conflicts of interest. </p> </section> <section id="CD001392-sec-0088"> <h3 class="title" id="CD001392-sec-0088">Agreements and disagreements with other studies or reviews</h3> <p>Emergence of drug resistance was reported by <a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> and was repeatedly reproduced by newer studies with follow‐up longer than six months (<a href="./references#CD001392-fig-0015" title="">Analysis 1.9</a>). Widespread use of antibiotics poses a high likelihood of inducing substantial population‐level antibiotic resistance in a range of micro‐organisms (<a href="./references#CD001392-bbs2-0281" title="SerisierDJ . The evidence base for non‐CF bronchiectasis is finally evolving. Respirology2014;19(3):295‐7. ">Serisier 2014</a>). In particular, the long‐acting agent azithromycin rapidly induces sustained macrolide resistance, and its introduction in the USA in 1992 was temporally associated with a substantial increase in rates of macrolide resistance in pneumococcal isolates (<a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a>). This review was limited to emergence of drug resistance among participants; however, available evidence from this review supports the imperative importance of patient selection for intervention, especially with long‐acting antibiotics. The process of patient selection can be assisted by the bronchiectasis severity index (BSI), which is based on prior hospital admission(s), Medical Research Council dyspnoea score greater than or equal to 4, forced expiratory volume in one second (FEV1) &lt; 30% predicted, <i>Pseudomonas aeruginosa</i> colonisation, colonisation with other pathogenic organisms and three or more lobes involved as seen on high‐resolution computed tomography (<a href="./references#CD001392-bbs2-0256" title="ChalmersJD , GoeminneP , AlibertiS , McDonnelM , LonniS , DavidsonJ , et al. The Bronchiectasis Severity Index. An international derivation and validation study. American Journal of Respiratory and Critical Care Medicine2013;189:576‐85. ">Chalmers 2013</a>), which was validated across five cohorts (1310 participants) with four‐year follow‐up. Similar clinical domains were based on another score called "FACED" (F for forced expiratory volume in one second; A for Age; C for <i>Pseudomonas</i> colonisation; E for extent of bronchiectasis counting lobar involvement on CT scan; and D for dyspnoea, using the Medical Research Council dyspnoea score proposed by Martinez‐Garcia et al, with an intent to predict five‐year mortality in mild, moderate and severe disease (defined as scores of 0 to 2, 3 to 4 and 5 to 7, respectively) of 4%, 25% and 56%, respectively (<a href="./references#CD001392-bbs2-0269" title="Martinez‐GarciaMA , deGraciaJ , VendrellRM . Multidimensional approach to non‐cystic fibrosis bronchiectasis: the FACED score. European Respiratory Journal2014;43:1357‐67. ">Martinez‐Garcia 2014</a>; <a href="./references#CD001392-bbs2-0277" title="SalehA , HurstJ . How to assess the severity of bronchiectasis. European Respiratory Journal2014;45:1217‐9. ">Saleh 2014</a>). Moreover, the development of multi‐drug‐resistant organisms among patients with drug allergy will add extra burden. Therefore, in clinical practice, conscientious selection of an appropriate intervention for each patient is of utmost importance. </p> <p>Another recent review of long‐term macrolides for non‐cystic fibrosis bronchiectasis found that macrolides were a reliable treatment option for individuals with stable bronchiectasis, as revealed by available data (<a href="./references#CD001392-bbs2-0287" title="WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Wu 2014</a>). However, similar to our review, for outcomes such as macrolide resistance, meta‐analysis of all included studies was not possible because outcome data were incompletely reported. Authors of the <a href="./references#CD001392-bbs2-0287" title="WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Wu 2014</a> review conclude that their results justify further investigation of macrolides in combination with usual treatment regimens for bronchiectasis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001392-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001392-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001392-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), outcome: 1.1 Exacerbations." data-id="CD001392-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), outcome: 1.1 Exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Absolute treatment differences for exacerbations with events occurring in 546 per 1000 in the control arm and in 271 per 1000 (95% CI 126 to 385) people on the intervention." data-id="CD001392-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Absolute treatment differences for exacerbations with events occurring in 546 per 1000 in the control arm and in 271 per 1000 (95% CI 126 to 385) people on the intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Absolute treatment differences for hospitalisations with events occurring in 87 per 1000 in the control arm and in 37 per 1000 (95% CI 13 to 96) on the intervention." data-id="CD001392-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Absolute treatment differences for hospitalisations with events occurring in 87 per 1000 in the control arm and in 37 per 1000 (95% CI 13 to 96) on the intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Absolute treatment differences for emergence of antibiotic resistance with events occurring in 47 per 1000 in the control arm and in 148 per 1000 (95% CI 56 to 334) on the intervention." data-id="CD001392-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Absolute treatment differences for emergence of antibiotic resistance with events occurring in 47 per 1000 in the control arm and in 148 per 1000 (95% CI 56 to 334) on the intervention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 1 Exacerbations." data-id="CD001392-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 1 Exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 2 Hospitalisations." data-id="CD001392-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 2 Hospitalisations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 3 Response rates." data-id="CD001392-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 3 Response rates. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 4 Lung function." data-id="CD001392-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 4 Lung function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 5 Sputum leucocytes." data-id="CD001392-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 5 Sputum leucocytes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 6 Erythrocyte sedimentation rate (ESR)." data-id="CD001392-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 6 Erythrocyte sedimentation rate (ESR). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 7 Adverse events." data-id="CD001392-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 7 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 8 Deaths." data-id="CD001392-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 8 Deaths. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 9 Emergence of resistance." data-id="CD001392-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 9 Emergence of resistance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 10 Exercise capacity (6MWD)." data-id="CD001392-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 10 Exercise capacity (6MWD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 11 Change in St George Respiratory Questionnaire." data-id="CD001392-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 11 Change in St George Respiratory Questionnaire. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 12 Number of participants with exacerbations." data-id="CD001392-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 12 Number of participants with exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 13 Exacerbation rates ‐ continuous." data-id="CD001392-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 13 Exacerbation rates ‐ continuous. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 1 Exacerbations." data-id="CD001392-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 1 Exacerbations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 2 Hospitalisations." data-id="CD001392-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 2 Hospitalisations. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 3 Lung function." data-id="CD001392-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 3 Lung function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 4 Sputum leucocytes." data-id="CD001392-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 4 Sputum leucocytes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 5 Erythrocyte sedimentation rate (ESR)." data-id="CD001392-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 5 Erythrocyte sedimentation rate (ESR). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 6 Emergence of resistance." data-id="CD001392-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 6 Emergence of resistance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 7 Exercise capacity (6MWD)." data-id="CD001392-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 7 Exercise capacity (6MWD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001392-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/urn:x-wiley:14651858:media:CD001392:CD001392-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_t/tCD001392-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 8 Change in St George Respiratory Questionnaire." data-id="CD001392-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups), Outcome 8 Change in St George Respiratory Questionnaire. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/media/CDSR/CD001392/image_n/nCD001392-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001392-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prolonged antibiotics for purulent bronchiectasis in children and adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prolonged antibiotics for purulent bronchiectasis in children and adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with purulent bronchiectasis<br/> <b>Settings:</b> <br/> <b>Intervention:</b> prolonged antibiotics </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Prolonged antibiotics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exacerbations</b> <br/> Number of events<br/> Follow‐up: 1.5 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>546 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>271 per 1000</b> <br/> (126 to 385) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.31</b> <br/> (0.12 to 0.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>654<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 studies reported data on hospitalisations; 10 dichotomous studies are reported here. Generic inverse variance combining dichotomous and continuous data produced statistical significance in favour of antibiotic arm (OR 0.31, 95% CI 0.19 to 0.52; I² = 51%; P value &lt; 0.00001) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hospitalisations</b> <br/> Number of events<br/> Follow‐up: 1.5 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> <br/> (13 to 96) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> <br/> (0.14 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>643<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cross‐over study <a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> (n = 30 participants) also reported on hospitalisations with mean (± SD) improvement of 0.15 ± 0.37 observed in antibiotic arm compared with 0.75 ± 1.16 in placebo arm at 13 month follow‐up </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Emergence of resistance</b> <br/> Number of events<br/> Follow‐up: 1.5 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>148 per 1000</b> <br/> (56 to 334) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.48</b> <br/> (1.20 to 10.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>431<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nine studies reported on emergence of resistance; however, because of variability in reporting of outcome data, only 6 could be meta‐analysed. No difference was observed between groups for the remaining 3 studies </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>St George Respiratory Questionnaire (SGRQ) total</b> <br/> Mean and standard deviation. Scale from 0 to 100<br/> Follow‐up: 6 to 16 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ (total) score ranged across control groups from<br/> <b>‐6.4 to 4.1 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean SGRQ (total) score in intervention groups was<br/> <b>2.75 lower</b> <br/> (7.08 lower to 1.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>315<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life was reported in 10 studies, with meta‐analysis possible in 5. Substantial heterogeneity was observed between studies. Although sensitivity analysis using a fixed‐effect model produced statistically significant results, primary analysis using a random‐effects model was not statistically significant </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Presence of heterogeneity in 30% to 60% range, representing possibility of moderate heterogeneity.<br/> <sup>b</sup>Small number of events producing wide confidence intervals around estimate of effect.<br/> <sup>c</sup>Presence of heterogeneity in 75% to 100% range, representing possibility of considerable heterogeneity. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Prolonged antibiotics for purulent bronchiectasis in children and adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001392-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Search years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Detail</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All years to January 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N citations retrieved: 447<br/> N studies included: 6 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>January 2003 to January 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No new studies identified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>January 2004 to January 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No new studies identified</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>January 2005 to January 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N citations retrieved: 11<br/> N retrieved: 4<br/> N included: 3 </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Search history</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001392-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Age (mean ± SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b> Participants (N)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Follow‐up (weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Int</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Cont</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Int</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Cont</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/NZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.99 ± 2.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.22 ± 2.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 ± 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 ± 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a>a </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.1 ± 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.5 ± 9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a>b </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/NZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 ± 5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.5 ± 13.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.9 ± 12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 ± 9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aust; Germany; Spain; Sweden; UK; USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.7 ± 11.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4 ± 11.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.9 ± 13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.0 ± 13.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scotland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (53‐67)‡</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (55.7‐69)‡</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1 ± 2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9 ± 2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.8 ± 9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.8 ± 9.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 to 56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5 (38‐75)†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.5 (38‐75)†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.0 ± 8.5¶</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4 ± 10.3¶</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 ± 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 ± 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.3 ± 2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.9 ± 2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int 1: 34.3; Int 2: 32.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int 1: 36; Int 2: 44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>* = median; † = mean and range; ‡ = median and IQR; ¶ = mean + SE.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001392-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Types of interventions and status of Pseudomonas aeruginosa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with PA (baseline)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patients with PA (end of intervention)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antibiotics</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delivery mode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Int duration (weeks)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up (weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0001" title="AltenburgJ . Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non‐cystic fibrosis bronchiectasis. JAMA2013;209(12):1251‐9. AltenburgJ , deGraaffC , van derWerfT , BoersmaW . Long‐term azithromycin treatment: a randomised placebo‐controlled trial in non‐CF bronchiectasis; results from the BAT trial. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011; Vol. 38. BoersmaWG , AltenburgJ , WerfTS . Evaluation of symptoms score and QOL in azithromycin maintenance treatment: results of a RCT trial in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3658. ">Altenburg 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/43 on intervention, 6/40 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43 on intervention, 4/40 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0005" title="DeDiegoA , MilaraJ , Martinez‐MoragonE , PalopM , LeonM , CortijoJ . Effects of long‐term azithromycin therapy on airway oxidative. Respirology (Carlton, Vic.)2013;18(7):1056‐62. ">De Diego 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/16 on intervention, 5/14 on control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/16 on intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12#</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a> BLESS </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/59 on intervention, 18/58 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/59 on intervention, 17/58 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0015" title="MobberleyC , KakeS , FaasaleleH , PatersonJ , ByrnesCA . Improving enrolment and retention of Maori and Pacifica families in respiratory research. Respirology2011;16(Suppl):TP‐135. ValeryP , MorrisPS , ByrnesCA , GrimwoodK , TorzillaPJ , BauertPA , et al. Long‐term azithromycin for indigenous children with non‐cystic fibrosis bronchiectasis or chronic suppuratives lung disease (Bronchiectasis Intervention Study): a multicentre, double‐blind, randomised controlled trial. Lancet Respiratory Medicine2013;1:610‐20. ValeryPC , MorrisPS , GrimwoodK , TorzilloPJ , ByrnesCA , MastersBI , et al. Azithromycin for Indigenous children with bronchiectasis: study protocol for a multi‐centre randomised controlled trial. BMC Pediatrics2012;12:122‐31. ">Valery 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45 on intervention, 0/44 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/45 on intervention, 0/44 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.8 (mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0008" title="LiuJF , ZhongXN , HeZY , ZhongDJ , BaiJ , ZhangJQ , et al. [Impact of treatment with low dose roxithromycin on stable bronchiectasis]. Zhonghua Jie He He Hu Xi Za Zhi [Chinese Journal of Tuberculosis and Respiratory Diseases]2012;35(11):824‐7. WuQ , ShenW , ChengH , ZhouX . Long‐term macrolides for non‐cystic fibrosis bronchiectasis: a systematic review and meta‐analysis. Respirology2014;19(3):321‐9. ">Liu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0017" title="JayaranL , WongCA , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. Respirology2012;17:35. WongC , JayaramL , KaralusN , EatonT , TongC , HockeyH , et al. Azithromycin for prevention of exacerbation in non‐cystic fibrosis bronchiectasis (EMBRACE): a randomised, double‐blind, placebo‐controlled trial. Lancet2012;380:660‐7. WongCA , JayaramL , KaralusN , EatonT , TongC , HockeyH . Azithromycin decreases exacerbations in non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2012;185:A3657. ">Wong 2012</a> EMBRACE </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/71 on intervention, 8/70 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/46 on intervention, 5/45 on placebo*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0018" title="YalcinE , KiperN , OzcelikU , DogruD , FiratP , SahinA , et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics2006;31(1):49‐55. ">Yalçin 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clarithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0004" title="CymbalaAA , EdmondsLC , BauerMA , JederlinicPJ , MayJJ , VictoryJM , et al. The disease‐modifying effects of twice‐weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine2005;4(2):117‐22. ">Cymbala 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usual care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 to 56</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0014" title="TsangKW , HoPI , ChanKN , IpMS , LamWK , HoCS , et al. A pilot study of low‐dose erythromycin in bronchiectasis. European Respiratory Journal1999;13(2):361‐4. TsangKW , HoPL , HoCS , ChanKN , IpM , LamWK , et al. Erythromycin reduces sputum volume and improves lung functions in bronchiectasis. American Journal of Respiratory and Critical Care Medicine1998;157(Suppl 3):A174. ">Tsang 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/11 on intervention, 6/10 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erthromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0007" title="KohYY , LeeMH , SunYH , SungKW , ChaeJH . Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double‐blind, placebo‐controlled study. European Respiratory Journal1997;10(5):994‐9. ">Koh 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Roxithromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0003" title="CurrieDC , GarbettND , ChanKL , HiggsE , ToddH , NunnAJ , et al. Double blind randomised placebo controlled study of long term high dose antibiotic in patients with bronchiectasis. Clinical Research1987;72(Suppl 16):79P. CurrieDC , GarbettND , ColePJ . Double‐blind randomized study of prolonged higher‐dose oral amoxycillin in purulent bronchiectasis. Quarterly Journal of Medicine1990;76(280):799‐816. ">Currie 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/17 on intervention, 7/19 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/17 on intervention, 4/19 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amoxycillin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001392-bbs2-0009" title="Medical Research Council. Prolonged antibiotic treatment of severe bronchiectasis: a report by a subcommittee of the Antibiotics Clinical Trials (Non‐Tuberculous) Committee of the Medical Research Council. British Medical Journal1957;2:255‐9. ">MRC 1957</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Int 1: penicillin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Int 2: oxytetracycline</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0280" title="SerisierDJ . Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respiratory Medicine2013;1:262‐74. ">Serisier 2013</a> ORBIT </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/20 on intervention, 22/22 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/20 on intervention, 19/22 on placebo†</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0016" title="AlderJ , WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH . Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non‐cystic fibrosis bronchiectasis. European Respiratory Society 21st Annual Congress; 2011 Sep 24‐28; Amsterdam. 2011. AntoniuS , AzoicaiD . Ciprofloxacin DPI in non‐cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs2013;22(5):671‐3. WilsonR , WelteT , PolverinoE , DeSoyzaA , GrevilleH , O’DonnellA , et al. Ciprofloxacin dry powder for inhalation in non‐cystic fibrosis bronchiectasis: a phase II randomised study. European Respiratory Journal2013;41(5):1107‐15. WilsonR , WelteT , PoverinoE , DiSoyzaA , GrevilleH , O'DonnellA . Randomized, placebo‐controlled, double‐blind, multi‐center study to evaluate the safety and efficacy of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo In patients with non‐cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:A6407. ">Wilson 2013a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/60 on intervention, 35/64 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/40 on intervention, 4/49 on placebo‡</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ciprofloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inhaled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0006" title="DrobnicME , SuneP , MontoroJB , FerrerA , OrriolsR . Inhaled tobramycin in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa . Annals of Pharmacotherapy2005;39(1):39‐44. ">Drobnic 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/30 on intervention, 30/30 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/30 on intervention§</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0002" title="BarkerAF , CouchL , FielSB , GotfriedMH , IlowiteJ . Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine2000;162(2 Pt 1):481‐5. CouchLA . Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa . Chest2001;120(3):114S‐17S. FielSB . The relationship between antimicrobial efficacy and improved medical condition in tobramycin solution for inhalation therapy in bronchiectasis. European Respiratoy Journal2000;16(Suppl 31):494s. O'DonnellA , TullyH , KylstraJW , WellsC , SchaefflerB , BarkerAF . Tobramycin solution for inhalation (TOBI) as maintenance treatment for bronchiectasis patients with Pseudomonas aeruginosa. Thorax1999;54(Suppl 3):A68. ">Barker 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37/37 on intervention, 37/37 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/37 on intervention, 0/37 on placebo*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0011" title="OrriolsR , RoigJ , FerrerJ , SampolG , RosellA , FerrerA , et al. Inhaled antibiotic therapy in non‐cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respiratory Medicine1999;93(7):476‐80. ">Orriols 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/7 on intervention, 8/8 on control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/7 on intervention, 8/8 on control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ceftazidime/tobramycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001392-bbs2-0010" title="AntoniuSA , TroforAC . Inhaled gentamicin in non‐cystic fibrosis bronchiectasis: effects of long‐term therapy. Expert Opinion on Pharmacotherapy2011;12(7):1191‐4. MurrayM , GovanJ , DohertyC , SimpsonA , WilkinsonT , ChalmersJ , et al. A randomized controlled trial of nebulized gentamicin in non–cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine2011;183:491‐9. ">Murray 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/27 on intervention, 11/30 on placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/13 on intervention*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gentamicin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nebulised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>PA = <i>Pseudomonas aeruginosa</i> . *Eradicated. †At day 28. ‡Negative bacterial culture at end of intervention. §Transient disappearance of <i>Pseudomonas</i> in culture. #Actual follow‐up period was not reported. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Types of interventions and status of Pseudomonas aeruginosa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/full#CD001392-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001392-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Continuous antibiotics versus standard treatment with or without added placebo (parallel groups)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.19, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospitalisations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.14, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Response rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.14, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Lung function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 FEV1 % predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.34, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Change in FEV1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.84, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 FEV1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐1.03, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Sputum leucocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.87, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Erythrocyte sedimentation rate (ESR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.47 [‐9.76, 4.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Withdrawals (intolerable side effects)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.56, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.33 [1.50, 7.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.67, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Wheeze</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.56 [1.63, 44.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Dyspnoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [1.43, 13.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.6 Chest pain/palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.21 [1.35, 20.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.7 Increased cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.48, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.8 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.45, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.9 Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.30, 3.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.10 Hemoptysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.45, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.11 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.17, 2.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.12 Increased sputum</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.53, 5.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.13 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.10 [1.38, 18.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.14 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.15 Bronchospasm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.76, 6.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.16 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.37 [0.07, 290.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.17 Acute sinusitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.05, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.28, 7.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Emergence of resistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.48 [1.20, 10.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Exercise capacity (6MWD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.22, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change in St George Respiratory Questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.16 [‐40.22, 11.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.75 [‐7.08, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Number of participants with exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.19, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Exacerbation rates ‐ continuous <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.32, ‐0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Continuous antibiotics versus standard treatment with or without added placebo (parallel groups)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001392-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Exacerbations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.25, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospitalisations <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.23, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Lung function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 FEV1 % predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.34, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Change in FEV1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.47, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 FEV1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐1.03, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Sputum leucocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.87, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Erythrocyte sedimentation rate (ESR) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.04 [‐8.76, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Emergence of resistance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.65 [1.74, 7.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Exercise capacity (6MWD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.22, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in St George Respiratory Questionnaire <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.19 [‐14.32, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.29 [‐4.69, 0.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sensitivity analysis (fixed effect): continuous antibiotics versus standard treatment with or without added placebo (parallel groups)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001392.pub3/references#CD001392-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001392.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001392-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001392-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD001392-note-0001">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001392\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001392\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001392\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001392\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001392\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001392.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001392.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001392.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001392.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001392.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717982808"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001392.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717982813"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001392.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc53439c9f49c',t:'MTc0MDcxNzk4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 